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Antibodies are glycoproteins produced by terminally differentiated B cells known as 
plasma cells. They are the central effectors of adaptive immunity, as they specifically 
bind invading pathogens leading to their neutralization. Besides their substantial function 
in the immune system, they are used as monoclonal antibodies for the treatment of many 
diseases, including cancer and autoimmune disorders, and are therefore produced 
recombinantly in large numbers. In the form of autoantibodies, on the other hand, 
antibodies may represent disease causing and promoting molecules. 
All processes mediated by antibodies rely on a functional, three-dimensional structure, 
which in turn is attained in the endoplasmatic reticulum (ER) and aided by several ER-
resident chaperones and folding catalysts. Therefore, a profound knowledge of antibody 
folding is substantial not only to gain a deeper understanding of the immune system, but 
also to improve recombinant antibody folding and to develop novel strategies to deal with 
autoimmune diseases. Still, antibody folding is insufficiently characterized so far. Here, 
expression, localization, regulation and function of FKBP11, a potential novel antibody 
folding peptidyl-prolyl cis-trans isomerase (PPIase), was analyzed. 
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease (ILD) with increasing 
incidence worldwide and a poor prognosis with median survival rates of 3-5 years upon 
diagnosis. It is a fibrotic disease defined by an excessive deposition of extracellular matrix 
(ECM) resulting in an irreversible, ultimately fatal disruption of the lung architecture. 
Treatment with the Food and Drug Administration (FDA) approved antifibrotic 
compounds pirfenidone and nintedanib can slow down disease progression, but does not 
stop it, highlighting the need for a better understanding of this disease along with novel 
treatment strategies. Importantly, there is emerging evidence of autoimmune features 
present in IPF, including lymphocytic aggregates within IPF lung tissue and elevated 
levels of autoantibodies in the serum of IPF patients. A better understanding of these 
features could provide novel therapeutic targets in the treatment of IPF. 
Consistent with preceding proteomics data, protein levels of FKBP11 were highly 
increased in lung tissue of IPF patients. In IPF lungs, immunofluorescence revealed that 
FKBP11 was specifically expressed by CD27+/CD38+/CD138+/CD3-/CD20-/CD45- 
plasma cells, the number of which was drastically elevated in IPF lungs. Accordingly, in 
vitro B cell to plasma cell differentiation induced by a mixture of Interleukin-2 (IL-2) and 
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R848 (resiquimod) was accompanied by an upregulation of FKBP11. More specifically, 
FKBP11 was upregulated as a part of the unfolded protein response (UPR) in an XBP1-
dependent manner, with XBP1 being an important driver of the plasma cell differentiation 
process. This was assessed by artificial induction of ER stress using tunicamycin upon 
two different cell lines. Interestingly, prior knockdown of FKBP11 made the cells more 
susceptible to ER stress induced cell death. Finally, the function of FBKP11 was 
determined using an in vitro antibody folding assay, showing that addition of human 
recombinant FKBP11 increased both the speed of antibody folding as well as total yields 
of correctly folded antibodies. This effect was inhibited by prior incubation of FKBP11 
with tacrolimus (FK506). In agreement with a function in antibody folding, knockdown 
of FKBP11 in an antibody secreting hybridoma cell line reduced antibody levels in the 
cell culture supernatant. 
Overall, FKBP11 was identified as a novel, plasma cell specific antibody folding catalyst 
in IPF. This provides new insights into plasma cell biology and the process of antibody 
folding, supporting a role of autoimmunity in IPF and allowing for the conception of 
innovative, targeted therapies not only in IPF, but also in autoimmune disorders. 
Moreover, these insights may help to overcome present limitations in the production of 
therapeutic, monoclonal antibodies. 
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Zusammenfassung 
Antikörper sind Glykoproteine, die von ausdifferenzierten B-Zellen, den Plasmazellen, 
produziert werden. Sie sind zentraler Bestandteil des adaptiven Immunsystems, indem sie 
eingedrungene Erreger binden und somit zu deren Beseitigung führen. Außerdem werden 
sie als monoklonale Antikörper zur Behandlung vieler Krankheiten, wie etwa Krebs und 
Autoimmunerkrankungen, genutzt und daher in großen Mengen rekombinant hergestellt. 
Andererseits können Antikörper auch in Form von Autoantikörpern zur Entstehung von 
Krankheiten führen und diese aufrecht erhalten. 
All diese Prozesse, die durch die Bindung von Antikörpern ausgelöst werden, erfordern 
eine funktionierende, dreidimensionale Struktur des Antikörpers, die unter Zuhilfenahme 
von Chaperonen und Faltungskatalysatoren im endoplasmatischen Retikulum (ER) 
entsteht. Daher ist ein tiefgreifendes Verständnis von Antikörperfaltung nicht nur 
wesentlich, um neue Erkenntnisse zum Immunsystem zu gewinnen, sondern kann auch 
die rekombinante Herstellung monoklonaler Antikörper verbessern sowie dazu beitragen, 
neue Strategien zur Behandlung von Autoimmunerkrankungen zu gewinnen. Bislang ist 
der Vorgang der Antikörperfaltung jedoch unzureichend dargestellt worden. In dieser 
Arbeit wurde die Expression, Lokalisation, Regulation sowie Funktion von FKBP11, 
einer Peptidyl-Prolyl-cis/trans-Isomerase (PPIase), im Hinblick auf eine mögliche 
Funktion als antikörperfaltendes Enzym analysiert. 
Die idiopathische Lungenfibrose (IPF) gehört zu den interstitiellen Lungenerkrankungen 
(ILDs) und hat eine schlechte Prognose mit einer mittleren Überlebenszeit von 3-5 Jahren 
bei Diagnosestellung. Die Inzidenz der IPF ist weltweit steigend. Die Krankheit ist 
gekennzeichnet durch eine zunehmende Vernarbung (Fibrosierung) des Lungengewebes, 
die durch eine enorme Ablagerung von extrazellulärer Matrix (ECM) gekennzeichnet ist. 
Dies führt zu einer zunehmenden Zerstörung der Lungenarchitektur, die am Ende zum 
Tod der Patienten führt. Die derzeit von der Arzneimittelzulassungsbehörde der USA 
(Food and Drug Administration, FDA) zugelassenen, anti-fibrotischen Medikamente, 
namentlich Pirfenidon und Nintedanib, verlangsamen lediglich das Voranschreiten der 
Erkrankung, verhindern es jedoch nicht. Dies verdeutlicht, dass ein besseres Verständnis 
der IPF notwendig ist, um neue Behandlungsansätze zu identifizieren. Weiterhin wird 
zunehmend ersichtlich, dass Eigenschaften von Autoimmunerkrankungen in der IPF zu 
finden sind, wie etwa lymphozytäre Infiltrate in den Lungen der Patienten sowie 
zirkulierende Autoantikörper im Serum der Patienten. Eine bessere Charakterisierung 
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dieser autoimmunen Eigenschaften in der IPF könnte dazu führen, neue 
Behandlungsansätze zu verwirklichen. 
Übereinstimmend mit einer vorhergehenden Proteomikstudie der IPF zeigten 
Lungengewebeproben von IPF-Patienten höhere Proteinmengen von FKBP11. In der 
Immunfluoreszenz war ersichtlich, dass FKBP11 in IPF Lungen ausschließlich von 
Plasmazellen (CD27+/CD38+/CD138+/CD3-/CD20-/CD45-) exprimiert wird. 
Entsprechend war die Zahl der Plasmazellen in IPF-Lungen deutlich erhöht. Damit 
übereinstimmend führte eine in vitro Plasmazelldifferenzierung mithilfe von Interleukin-
2 (IL-2) und R848 (Resiquimod) zu einer Hochregulierung von FKBP11. Eine künstliche 
Herbeiführung von ER-Stress mittels Tunicamycin in zwei unabhängigen Zelllinien 
führte zur Hochregulierung der ungefalteten Protein-Antwort (UPR) und zeigte auf, dass 
FKBP11 als Teil der UPR in der Plasmazelldifferenzierung hochreguliert wird. Genauer 
noch bestätigte der vorhergehende Knockdown von XBP1, einem wichtigen 
Transkriptionsfaktor der Plasmazelldifferenzierung, dass die Hochregulierung von 
FKBP11 über XBP1 vermittelt wird. Weiterhin zeigte sich bei Herbeiführung von ER-
Stress nach vorhergehendem Knockdown von FKBP11 eine erhöhte Empfindlichkeit der 
Zellen gegenüber ER-Stress-induziertem Zelltod. Letztlich konnte durch ein in vitro 
Antikörperfaltungssystem demonstriert werden, dass rekombinantes, humanes FKBP11 
die Fähigkeit besitzt, Antikörper in vitro zu falten, da es sowohl den Faltungsprozess 
selbst beschleunigte, als auch den Ertrag an korrekt gefalteten Antikörpern steigerte. 
Diese Effekte konnten durch vorhergehende Inkubation von FKBP11 mit Tacrolimus 
(FK506) verhindert werden. Damit übereinstimmend führte ein Knockdown von FKBP11 
in einer antikörperproduzierenden Hybridomzelllinie zu geringeren 
Antikörperkonzentrationen im Zellkulturüberstand. 
Abschließend lässt sich sagen, dass mit FKBP11 ein neuartiges Protein identifiziert 
wurde, das in der Lage ist, Antikörper in Plasmazellen zu falten. Dies gewährt neuartige 
Einblicke in die Biologie der Plasmazelle sowie den Prozess der Antikörperfaltung, und 
unterstützt weiterhin die Rolle von Autoimmunität in der IPF. Dies ermöglicht die 
Entwicklung neuartiger Therapieansätze, sowohl in der Behandlung der IPF, als auch in 
der Behandlung von Autoimmunerkrankungen. Darüber hinaus können diese 





1.1 The innate and adaptive immune system: An overview 
The human organism is permanently exposed to a wide variety of pathogens, including 
bacteria, viruses, and parasitic worms. To be protected from these, the human organism 
evolved a host defense system known as the immune system, which consists of two major 
immune strategies: the innate immune system and the adaptive immune system. Both 
subsystems possess humoral and cell-mediated mechanisms to face pathogens (Marrack 
and Kappler 1994). 
If a pathogen breaks through the body’s surface barriers (e.g. skin, mucous membranes), 
the innate immune system provides a first line, however, non-specific reaction. This 
reaction is triggered by highly conserved pattern recognition receptors (PRRs), such as 
toll-like receptors (TLRs), which bind highly conserved components expressed on the 
surface of the invading pathogens, for instance, pathogen-associated molecular patterns 
(PAMPs). Cells participating in the innate immune system include phagocytes 
(neutrophils, macrophages, dendritic cells), innate lymphoid cells, mast cells, eosinophils, 
basophils and natural killer cells. The humoral component of innate immunity is achieved 
by the complement system, a biochemical cascade attacking the surface of invading cells 
(Chaplin 2010). 
In case that a pathogen evades the innate immune system, a second layer of protection is 
provided via the adaptive immune system. In contrast to the innate immune system, the 
adaptive immune system is highly specific towards distinct antigens and requires 
activation by the innate immune system. This second line reaction is carried out by B 
cells and T cells, carrying a wide variety of distinct receptors (B cell receptors: BCR, T 
cell receptors: TCR), corresponding to a wide variety of distinct antigens. In order for a 
B cell or T cell to identify a receptor specific antigen, it needs to be presented by the 
major histocompatibility complex (MHC). The presentation of the antigen in the MHC is 
realized by antigen presenting cells (APCs). After activation, B cells mediate the humoral 
component of the adaptive immune system via secretion of soluble antibodies. T cells, on 
the other hand, act as the cellular component (Hoebe, Janssen et al. 2004, Chaplin 2010). 
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1.2  B cells in the adaptive immune system 
1.2.1 B cell development 
As outlined above, B cells represent the humoral branch of the adaptive immune system 
by secretion of soluble antibodies (also known as immunoglobulins, Igs). Once fully 
matured and activated, they are referred to as plasma cells and secrete antibodies with a 
single defined antigen specificity, which is accomplished by a complicated 
developmental process originating in the bone marrow from hematopoietic stem cells 
(HSCs). The high diversity of antibodies matching almost any potential antigen is attained 
during B cell development by joining separate gene segments randomly together before 
their transcription is initiated, a process known as V(D)J recombination, with the letters 
standing for variable (V), joining (J) and diversity (D) gene segments (Rolink, ten Boekel 
et al. 1999). 
Starting with early B cell development in the bone marrow, HSCs differentiate into 
multipotent progenitor cells (MPPs), followed by common lymphoid progenitor cells 
(CLPs). After completion of further developmental stages (pro-B cell, pre-B cell) in the 
bone marrow, each defined by distinct gene expression patterns and gene loci 
rearrangements, they become immature B cells. Of note, during early B cell development 
in the bone marrow, B cells start to undergo both positive and negative selection. As a 
consequence, the BCR is able to bind foreign antigens (positive selection), while not 
binding self-antigens (negative selection) (LeBien and Tedder 2008). 
After completing early B cell development in the bone marrow, the immature B cells 
transmigrate as transitional B cells (at this point in transitional state 1, T1) to the spleen, 
where they transit further transitional states, T2 and T3, finally differentiating into 
follicular (FO) or marginal zone (MZ) B cells. These steps within the spleen are 
considered as transitional B cell development. Once differentiated, they are referred to as 
mature (or naïve) B cells. Similar to early B cell development, both positive and negative 
selection processes occur during transitional B cell development. (Chung, Silverman et 
al. 2003).   
1.2.2 Activation of B cells 
B cell activation occurs in secondary lymphoid organs (SLOs), such as lymph nodes and 
spleen, finally resulting in differentiation into terminally differentiated B cells known as 
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antibody secreting cells (ASCs). There, naïve B cells get into contact with antigens 
delivered by circulating lymph and can be either activated in dependence of T cells, 
usually by T cell-dependent (TD) antigens, or without the help of T cells, usually by T 
cell-independent (TI) antigens. TD antigens include foreign proteins, TI antigens include 
foreign polysaccharides and unmethylated DNA (Cyster and Allen 2019). 
1.2.3 Differentiation of activated B cells into antibody secreting cells (ASCs) 
B cell activation finally results in the formation of antibody secreting cells (ASCs). ASCs 
include two subsets, namely plasmablasts (or immature plasma cells) and plasma cells. 
The latter are postmitotic and develop from plasmablasts. To be able to secrete vast 
amounts of antibodies (up to 10.000 antibodies per cell per second (Lanzavecchia 2018)), 
B cells need to undergo crucial changes during differentiation to ASCs with respect to 
cellular structure, metabolism and protein expression profile. ASCs expand their 
endoplasmatic reticulum (ER) along with upregulation of ER-resident chaperones and 
folding catalysts, as well as their Golgi apparatus. (Nguyen, Joyner et al. 2019). 
Therefore, the gene expression profile changes fundamentally, which is accomplished by 
silencing of transcription factors and repressors defining B cell identity and upregulation 
of factors driving ASC differentiation. Factors defining B cell identity include paired box 
protein 5 (PAX5), transcription regulator protein BACH2, and B cell lymphoma 6 (BCL-
6). The most important drivers of ASC differentiation are interferon regulatory factor 4 
(IRF4), PR domain zinc finger protein 1(PRDM1, also known as BLIMP-1) and X-box 
binding protein 1 (XBP1) (Nutt, Hodgkin et al. 2015). Along with the change in the gene 
expression profile, cell surface molecules change, which can be used as targets for 
immunophenotyping of cells. Table 1 summarizes important characteristics in gene 







Table 1: Overview of characteristics of naïve B cells and ASCs (plasmablasts and plasma 




Naïve B cells Plasmablasts Plasma cells 
Lifespan ++ + ++++ 
Proliferation - ++ - 
CD27, CD38, CD138 - + +++ 
CD19, CD20, CD45 +++ ++ +/- 
PRDM1 - + ++ 
 
1.2.4 Role of the unfolded protein response (UPR) in plasma cell differentiation 
Whenever protein folding is impaired in the ER, misfolded and unfolded proteins 
accumulate in the ER. This can be a consequence of an impaired ER resident folding 
machinery, an overload of proteins to be folded or a disrupted ER environment. The 
accumulation of misfolded proteins usually leads to the induction of ER stress, ultimately 
resulting in upregulation of the unfolded protein response (UPR), a highly conserved 
collection of intracellular signaling pathways. In the context of the UPR, translation of 
new protein is transiently paused, degradation of misfolded protein is supported and the 
secretory apparatus in the ER is expanded to recover maintenance of protein folding in 
the ER (Liu and Kaufman 2003).  
ER stress is detected by three transmembrane ER stress sensors: inositol-requiring 
enzyme 1α (IRE1α), PKR-like ER kinase (PERK) and activating transcription factor 6α 
(ATF6α). Under homeostatic conditions, these ER stress sensors remain inactive as a 
consequence of interaction with binding immunoglobulin protein (BiP, also known as 
GRP78). Once misfolded proteins accumulate, BiP dissociates from the ER stress sensors 
due to its higher affinity for misfolded proteins, resulting in release of the ER stress 
sensors. Subsequently, the ER stress sensors promote the UPR by several parallel 
pathways. Of these, the most conserved pathway is mediated by IRE1α, which, after 
autophosphorylation and forming dimers upon its release from BiP, exhibits RNase 
activity. With its RNase activity, the IRE1α dimer performs non-conventional splicing of 
a single mRNA encoding XBP1, resulting in a translational frameshift, finally creating a 
potent transcription factor known as XBP1s (spliced XBP1). XBP1s then induces a large 
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variety of ER-resident molecular chaperones and protein-folding enzymes, promoting the 
UPR. If the response is not sufficient, the UPR switches to a pro-apoptotic mode, known 
as terminal UPR, leading to apoptosis via upregulation of C/EBP homologous protein 
(CHOP); (Hetz and Papa 2018). 
In plasma cells, the ER and Golgi apparatus are strongly hypertrophied as compared to 
naïve B cells in order to fold enormous amounts of antibodies. This is accompanied by 
an upregulation of the ER-resident protein folding machinery necessary for sufficient 
folding of antibodies, consisting of molecular chaperones, peptidyl-prolyl cis-trans 
isomerases (PPIases), disulfide isomerases and glycosyl transferases. These changes 
occur during the process of B cell to plasma cell differentiation and are induced in the 
context of the UPR (Tellier and Nutt 2018). Notably, in B cell to plasma cell 
differentiation, the UPR is induced even before onset of Ig synthesis, indicating the UPR 
to be a physiological process of plasma cell differentiation rather than a stress induced 
response as in other cells (Grootjans, Kaser et al. 2016). Moreover, it has been implied 
that the pro-apoptotic pathway leading to upregulation of CHOP is selectively 
downregulated in order to be capable of dealing with enormous amounts of proteins (Ma, 
Shimizu et al. 2010). 
For upregulation of the UPR in plasma cell differentiation, the XBP1s pathway of the 
UPR was particularly shown to play a crucial role (Iwakoshi, Lee et al. 2003, Shaffer, 
Shapiro-Shelef et al. 2004). Of note, loss of XBP1 in B cells leads to an absence of plasma 
cells (Todd, McHeyzer-Williams et al. 2009). After activation of a naïve B cell, BCL-6, 
an important factor of B cell maintenance, is phosphorylated leading to its degradation. 
This results in de-repression of PRDM1, one of the main drivers for ASC differentiation. 
PRDM1 acts as a transcriptional repressor, and restrains, among other genes, the 
expression of PAX5, another key regulator of the B cell program. As a result, XBP1, 
which is usually repressed by PAX5, is activated, leading to induction of the UPR along 
with the ER-resident protein folding machinery (Grootjans, Kaser et al. 2016). This 
pathway is visualized in Figure 1. 
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Figure 1: Induction of the UPR as part of plasma cell differentiation. 
Activation of a naïve B cell by binding of an antigen to its B cell receptor (BCR) initiates the 
process of B cell to plasma cell differentiation. As a consequence, BCL-6 is phosphorylated, 
leading to its degradation, which then results in disinhibition of PRDM1 (BLIMP1). PRDM1 
promotes splicing of XBP1, inducing the UPR and plasma cell differentiation. ER = 
endoplasmatic reticulum. Figure modified from (Grootjans, Kaser et al. 2016). 
 
1.3 Antibodies as the final effectors of the humoral part of the adaptive 
immune system 
1.3.1 Structure of antibodies 
Antibodies (also known as immunoglobulins, Igs) represent the final effector molecules 
of the humoral part of the adaptive immune system. Once secreted, antibodies bind a 
unique site of a specific antigen, a so-called epitope, leading to its neutralization (Forthal 
2014).  
IgG, the most basic antibody isoform, is a Y-shaped, multidomain glycoprotein, 
consisting of two identical heavy chains (HCs), which are linked to each other via 
disulfide bonds, and two identical light chains (LCs), being attached to the HCs via 
disulfide bonds. The HC comprises four domains (three constant and one variable 
domain: CH1-3 and VH), the LC is half the size comprising two domains (constant and 
variable domain: CL and VL). IgG can be proteolytically cleaved into two Fab fragments 
(“fragment antigen binding”) and one Fc fragment (“fragment crystallizable”), being 
usually connected to each other by a hinge region. The amino-terminals ends of each Fab 
fragment, called paratopes, form variable domains, which bind specific, corresponding 
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epitopes of the antigen, while the remains of the Fab fragments as well as the Fc fragment 
make up the constant domains. The Fc fragment couples antigen binding to antibody 
effector functions (Figure 2) (Schroeder and Cavacini 2010). 
 
Figure 2: Structure of an IgG molecule (antibody).  
An IgG molecule is composed of two heavy (blue: VH, CH1, CH2, CH3) and two light chains 
(green: VL and CL), which are linked by disulfide bonds (S-S). The CH2 domains are further 
interconnected by oligosaccharides (grey hexagons). Figure adapted from (Feige, Hendershot et 
al. 2010). 
 
Depending on the type of heavy chain (α, δ, ε, γ and μ), different Ig isotypes can be 
distinguished: IgA, IgD, IgE, IgG and IgM (corresponding to the Greek letters). Every 
isotype has a different function. The types of light chains (κ and λ), on the other hand, are 
irrespective of the Ig subtype. While the antibody isotypes IgD, IgE and IgG are found in 
the monomeric form only, IgA and IgM exist as both monomeric and polymeric 
antibodies (Schroeder and Cavacini 2010). 
1.3.2 An overview of antibody folding  
Binding of specific antigens, finally mediating the effector function of the humoral part 
of the adaptive immune system, strictly relies on a functional, three-dimensional structure 
of the antibody (Tello, Spinelli et al. 1990). Therefore, correct folding of antibodies 
within the ER is essential, and checkpoints for correct protein structure must be controlled 
accurately. The folding process in the ER relies on several chaperones and folding 
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catalysts, including heat shock proteins (Hsp), peptidyl-prolyl cis-trans isomerases 
(PPIases), glycan-binding proteins and oxidoreductases, all of them being part of the ER-
resident protein folding machinery (Feige, Hendershot et al. 2010, Feige and Buchner 
2014). Most of them are upregulated during differentiation of naïve B cells to ASCs via 
the UPR, with XBP1 being a central transcription factor orchestrating the UPR in this 
differentiation process (Janssens, Pulendran et al. 2014). If folding is non-sufficient, and 
antibodies become terminally misfolded, they are marked for degradation by ER-
associated protein degradation (ERAD) by the proteasome (Qi, Tsai et al. 2017). 
HCs and LCs are co-translationally translocated into the ER, and before translation is 
finished, the folding process starts. All antibody domains except CH1 fold autonomously, 
reaching on-pathway intermediates within the folding process. The molecular chaperone 
BiP interoperates with most domains temporarily before their folding is finished. After 
CH3 is folded, dimerization of the HCs is induced, which will then be stabilized by 
formation of a disulfide bond in the hinge region. CH1 resides unfolded, being stabilized 
in its unfolded state by BiP, which also prevents secretion of single HCs. BiP is then 
dislocated by CL, with interaction of CL with CH1 inducing folding of CH1. Only after 
CH1 is folded correctly, disulfide bonds linking HCs and LCs to each other are formed, 
making the antibody ready for its secretion. By this mechanism, only correctly folded 
antibodies will leave the ER (Feige, Hendershot et al. 2010). A summary of the folding 
process in the ER is shown in Figure 3. 
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Figure 3: An overview on antibody folding in the ER. 
The molecular chaperone BiP temporarily interacts with most antibody domains. After CH3 is 
folded correctly, dimerization of the heavy chains is initiated. Importantly, CH1 is kept is an 
unfolded state by association with BiP, until the light chains displace BiP. This promotes folding 
of CH1, after which the disulfide bonds between heavy and light chains are formed, making the 
antibody molecule ready for secretion from the ER. Most of the individual folding steps are 
supported by chaperones, protein disulfide isomerases (PDIs) and peptidyl-prolyl cis-trans 
isomerases. Figure modified from (Feige, Hendershot et al. 2010). 
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1.3.3 Peptidyl-prolyl cis-trans isomerization in antibody folding 
In protein folding, peptidyl-prolyl cis-trans isomerizations are crucial, as they often 
represent rate limiting steps. Importantly, prolines constitute 5-10% of an antibody’s 
primary sequence. Accordingly, peptidyl-prolyl cis-trans isomerizations are an essential 
part of the antibody folding process (Feige and Buchner 2014). Peptidyl-prolyl cis-trans 
isomerizations are catalyzed by PPIases, which are grouped into two main families: 
FK506-binding proteins (FKBPs) and cyclophilins (Göthel and Marahiel 1999). More 
details on PPIases can be found in 1.4.1. Within antibody folding, only two PPIases being 
capable of antibody folding in vitro have been identified so far, namely Cyclophilin B 
(CypB) (Meunier, Usherwood et al. 2002, Feige, Groscurth et al. 2009, Jansen, Määttänen 
et al. 2012, Lee, Choi et al. 2012) and FKBP1A (also termed FKBP12) (Lilie, Lang et al. 
1993). 
1.3.4 Antibodies in autoimmune diseases: Autoantibodies 
As outlined above, B cells undergo both positive and negative selection during B cell 
development. However, if negative selection (also known as central tolerance) is non-
sufficient, B cells can secrete antibodies that react to self-molecules (autoantigens), 
leading to their destruction and ultimately promoting autoimmune diseases (Grimaldi, 
Hicks et al. 2005). 
Organ-specific autoimmune diseases, such as type 1 diabetes mellitus, primary biliary 
cirrhosis or thyroiditis, are characterized by the presence of autoantibodies highly specific 
for target organs (e.g. thyroglobulin in thyroiditis), leading to destruction of specific 
organs. In systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) 
or rheumatoid arthritis (RA), on the other hand, autoantibodies bind free molecules (e.g. 
phospholipids), resulting in formation of pathogenic antigen–antibody (immune) 
complexes. These complexes cause a non-specific inflammation of different organ 
systems (Davidson and Diamond 2001). 
Given the crucial role of B cells and autoantibodies in autoimmune diseases, a variety of 
treatment strategies has evolved specifically targeting B cells and autoantibodies 
(Hofmann, Clauder et al. 2018). One noteworthy example is rituximab, a monoclonal 
antibody directed against CD20, a pan B-cell surface protein. Binding of rituximab to 
CD20 triggers apoptosis, leading to specific depletion of the B cell lineage. This has been 
shown beneficial in many autoimmune diseases, including RA. (Gottenberg, Guillevin et 
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al. 2005). Moreover, there are monoclonal antibodies against CD19 (Mei, Schmidt et al. 
2012) and CD22 (Steinfeld and Youinou 2006), directly targeting distinct B cell subtypes. 
Other strategies include the proteasome inhibitor Bortezomib, leading to depletion of 
antibody secreting plasma cells (Alexander, Sarfert et al. 2015), and suppressants of B 
cell and plasma survival factors, such as B cell activating factor (BAFF) and A 
proliferation-inducing ligand (APRIL) (Samy, Wax et al. 2017). Another promising 
approach is extracellular cleavage of autoantibodies, as this has been shown effective in 
a murine model of RA (Nandakumar, Johansson et al. 2007). 
The process of antibody production within the ER, however, has barely been addressed 
as a target within autoimmune diseases so far. There is considerable treatment potential 
for development of novel treatment strategies directly targeting the process of 
autoantibody folding, which in turn requires further elucidation of the specific antibody 
folding machinery. 
1.4 FK506 binding proteins (FKBPs) 
1.4.1 Overview 
Immunophilins are highly conserved proteins and distributed across all tissues and 
organelles of the cell. Depending on which immunosuppressant drug they preferentially 
bind to, immunophilins can be subdivided into two subfamilies: Cyclophilins, binding to 
cyclosporin A (CsA), and FKBPs, binding to tacrolimus (also known as FK506 or 
fujimycin) or rapamycin (also known as sirolimus) (Amaravadhi and Ho Sup 2016). 
Both FKBPs and cyclophilins show intrinsic PPIase activity. Usually, peptide bonds, 
covalently linking consecutive amino acids, are energetically highly in favor of the trans 
state, meaning that the angle between the connected amino acids is ω=180°, and the Cα 
atoms of the connected amino acids are on opposite sides of the peptide bond. Peptide 
bonds with a preceding proline residue, however, are energetically only slightly more 
favorable of the trans state over the cis state (ω=0°), due to the cyclic side chain of 
proline, making isomerization from cis to trans state an intrinsically slow reaction with a 
high activation energy (~80 kJ/mol). As a consequence, peptidyl-prolyl cis-trans 
isomerizations often represent rate limiting steps in protein folding (Göthel and Marahiel 
1999). The chemical reaction is shown in Figure 4. 
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Figure 4: Peptidyl-prolyl cis-trans isomerization reaction.  
Figure adapted from (Göthel and Marahiel 1999). 
 
Along with their intrinsic PPIase activity, FKBPs have been shown to carry out numerous 
functions, including protein folding, chaperone activity, receptor signaling, protein 
trafficking and transcription (Kang, Hong et al. 2008). Moreover, FKBPs have been 
linked to various pathologies, including neurodegenerative disorders such as Alzheimer’s 
Disease (AD) and Parkinson’s Disease (PD) (FKBP1A, FKBP4, FKBP5), malignancies 
(FKBP4, FKBP5, FKBP8) and acquired and inherited, cardiac disease (FKBP1A) (Tong 
and Jiang 2015, Bonner and Boulianne 2017). This implies that a deeper understanding 
of FKBPs may provide novel insights on various pathologies, along with novel treatment 
strategies. 
1.4.2 Classification and structure of FKBPs 
So far, fifteen human FKBPs have been identified. Each FKBP contains at least one 
FK506-binding domain (FKBD), which usually shows PPIase activity. Moreover, FKBPs 
can contain further functional domains, such as calmodulin binding domains (CBDs), 
transmembrane motifs or tetratricopeptide repeat (TPR) domains, leading to versatile 
functions of each FKBP. Depending on their functional domains, FKBPs can be 
categorized into four subgroups: The cytoplasmic, nuclear, TPR domain and secretory- 
pathway FKBPs (Rulten, Kinloch et al. 2006). Figure 5 gives an overview of the domain 
structure of exemplary FKBP proteins. 
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Figure 5: Domain structure of exemplary FKBP proteins. 
Figure adapted from (Rulten, Kinloch et al. 2006). 
 
In the literature, FKBPs are either referred to according to their gene name, or according 
to their protein name, which is based on molecular weight. In the present study, gene 
names will be used as recommended by the Universal Protein resource (UniProt: 
http://www.uniprot.org/, Table 2). 
Table 2: Overview on the nomenclature of FKBP proteins. 
Molecular weight is indicated in kDa (kilodaltons). Table adapted from (Rulten, Kinloch et al. 
2006). 
Gene name  Protein name Molecular weight Subgroup 
FKBP1A FKBP12 12 kDa Cytoplasmatic 
FKBP1B FKBP12.6 12.6 kDa Cytoplasmatic 
FKBP3 FKBP25 19 kDa Nuclear 
FKBP15 FKBP133 133 kDa Nuclear 
FKBP4 FKBP52 52 kDa TPR-domain 
FKBP5 FKBP51 51 kDa TPR-domain 
FKBP6 FKBP36 36 kDa TPR-domain 
FKBP8 FKBP38 38 kDa TPR-domain 
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Table 2: Overview on the nomenclature of FKBP proteins. (continued) 
Gene name  Protein name Molecular weight Subgroup 
FKBP37.3 FKBP37 37 kDa TPR-domain 
FKBP7 FKBP23 23 kDa Secretory domain 
FKBP9 FKBP60 60 kDa Secretory domain 
FKBP10 FKBP65 65 kDa Secretory domain 
FKBP11 FKBP19 19 kDa Secretory domain 
FKBP14 FKBP22 22 kDa Secretory domain 
 
The prototype and most abundant FKBP member is FKBP1A, which has been 
characterized extensively. It is expressed ubiquitously and contains only a single FKBD 
domain (Figure 5) with high PPIase activity which can therapeutically be inhibited by 
tacrolimus. By binding of tacrolimus to FKBP1A, a binary complex is formed, which 
inhibits calcineurin. As a consequence, the nuclear-factor of activated T cells (NF-AT), a 
transcription factor necessary for upregulation of IL-2 in T cells, is no longer 
dephosphorylated, resulting in diminished activation and proliferation of T cells (Kang, 
Hong et al. 2008). 
1.4.3 FKBP11 
FKBP11 is an ER-resident PPIase and is strongly expressed in secretory tissues, including 
stomach, pancreas, pituitary glands and lymph nodes. It belongs to the subgroup of 
secretory pathway FBKPs, and is composed of an N-terminal signal sequence (in keeping 
with ER residency), a PPIase domain as well as a TM (Figure 5). It possesses a lysine-
rich C-terminal tail, which is often found in ER-membrane proteins. Due to its N-terminal 
signal sequence, anti-FKBP11 antibodies detect a doublet of 19-22 kDa corresponding to 
a mixture of FKBP11 either containing the N-terminal signal sequence or FKBP11 with 
a cleaved signal sequence. FBKP11 was shown to bind tacrolimus weakly in vitro, and is 
supposed to be involved in protein folding of secreted proteins and to act as a molecular 
chaperone (Rulten, Kinloch et al. 2006, Ishikawa, Mizuno et al. 2017). A distinct function 
or substrate, however, have not been characterized so far. 
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Interestingly, FBKP11 is suggested to play a role in B cell biology and (auto-)immunity: 
The transcriptome of B cells sorted from patients being in the non-active phase of SLE, 
a severe autoimmune disease, has been shown to express elevated levels of FKBP11. Of 
note, FKBP11 was elevated along with other genes associated with UPR (Garaud, 
Schickel et al. 2011). Furthermore, FKBP11high lentiviral mice have been reported to 
display elevated serum IgG levels, as well as a higher T cell-independent B cell response. 
Also, the same mice produced increased levels of autoantibodies, including anti-double 
stranded DNA, anti-thyroglobulin and anti-actin antibodies. In the same publication, 
FKBP11high lentiviral mice favored plasma cell differentiation, suggesting a role in B cell 
to plasma cell differentiation (Ruer-Laventie, Simoni et al. 2015). However, these effects 
have not been shown in a human model so far. 
Regulation of FKBP11 is thought to be associated with ER stress and the UPR (Wang, 
Cui et al. 2018). Various ER stress associated disorders display elevated levels of 
FKBP11, including SLE (Ruer-Laventie, Simoni et al. 2015), type 2 diabetes mellitus 
(Lu, Yang et al. 2008) and hepatitis (Lin, Yen et al. 2013). More recently, FKBP11 has 
been identified as a transcriptional target of XBP1, an important transcription factor 
within the UPR, in cardiomyocytes, and overexpression of XBP1 along with consequent 
upregulation of FKBP11 has led to cardiac growth, protecting from heart failure (Wang, 
Deng et al. 2019). 
1.5 Idiopathic pulmonary fibrosis (IPF) 
1.5.1 Overview of IPF 
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with median survival rates 
ranging from 3-5 years and increasing incidence worldwide. It is the most common type 
of interstitial lung diseases (ILDs), a large group of parenchymal lung diseases consisting 
of more than 200 diseases affecting the lung interstitium. In most patients, IPF presents 
with dyspnea and unproductive coughing. Further findings include myalgia and fine 
respiratory crackles upon auscultation. Ultimately, patients die due to asphyxiation 
caused by a severely disrupted gas exchange (King, Pardo et al. 2011, Nalysnyk, Cid-
Ruzafa et al. 2012). 
The histopathological hallmark of IPF is termed usual interstitial pneumonia (UIP), which 
is characterized by a heterogeneous pattern consisting of fibroblasts and myofibroblasts, 
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making up fibroblastic foci, and enormous amounts of deposited collagen and 
extracellular matrix (ECM). This results in a highly disorganized lung architecture, with 
honeycomb cyst formation corresponding to large spaces surrounded by fibrotic areas. 
So far, the mechanisms initiating these changes are not described precisely. Current 
concepts suggest that environmental threats, such as cigarette smoke, dust and infections, 
cause recurrent microinjuries to an inherently dysfunctional epithelium, resulting in 
leakage of the alveolar capillary barrier. Reparation processes then lead to activation of 
an abnormal remodeling, and finally to accumulation of fibrotic foci with excessive 
deposition of ECM. The most important profibrotic mediators in this process include 
transforming growth factor β1 (TGFβ1), vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) (Fernandez 
and Eickelberg 2012, Sgalla, Iovene et al. 2018, Butler and Keane 2019). Figure 6 gives 
a summary on important features in the pathogenesis of IPF. 
 
Figure 6: IPF pathogenesis. 
IPF is believed to be a result of repetitive microinjuries to a susceptible alveolar epithelium, 
resulting in fibroblasts differentiating into myofibroblasts with subsequent accumulation of 
extracellular matrix (ECM). This process is promoted by several growth factors, such as fibroblast 
growth factor (FGF) and transforming growth factor β (TGFβ), cytokines and chemokines. AEC 
= alveolar epithelial cell, MMP = matrix metalloproteinase. Figure adapted from (Butler and 
Keane 2019). 
 
The treatment approach towards IPF changed fundamentally within the last two decades. 
A nonspecific, immunosuppressive approach consisting of prednisolone and azathioprine 
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once being the standard therapy of IPF has been shown to go along with increased risk of 
death and hospitalization, and was therefore abandoned (Raghu, Anstrom et al. 2012). 
Only in the last few years, two novel antifibrotic medications, pirfenidone and nintedanib, 
were admitted for IPF therapy, and are both listed with “Conditional recommendation for 
use” in the “Official ATS/ERS/JRS/ALAT Clinical Practice Guideline” (Raghu, 
Rochwerg et al. 2015). Both compounds were shown to slow down the decline in lung 
function, however, they do not cease disease progression (Spagnolo, Tzouvelekis et al. 
2018). 
1.5.2 Autoimmune features in lung fibrosis and IPF 
Numerous systemic autoimmune diseases, including SLE, RA and systemic sclerosis, can 
affect the lung and lead to lung fibrosis (Mayberry, Primack et al. 2000). Underlying 
autoimmune processes involve inappropriate activation of autoreactive T cells as well as 
autoreactive B cells (Chizzolini 2008). Of note, experimental setups in the mouse model 
have shown that autoantibodies in particular can cause and deteriorate lung fibrosis 
(Komura, Yanaba et al. 2008, Shum, Alimohammadi et al. 2013, Vittal, Mickler et al. 
2013, Mehta, Goulet et al. 2016), while B cell depletion is protective towards 
development of lung fibrosis (Yoshizaki, Iwata et al. 2008, François, Gombault et al. 
2015, Matsushita, Kobayashi et al. 2018). 
In IPF, there is increasing evidence arguing for autoimmune features present in this 
disease. A recent proteomic study revealed elevated numbers of MZB1-positive plasma 
cells in lung tissues from IPF patients, as well as elevated IgG levels in the same tissues 
(Schiller, Mayr et al. 2017). In serum of IPF patients, an increased ratio of circulating 
plasmablasts has been detected, along with elevated Plasma B lymphocyte stimulating 
factor (BlyS), a soluble factor promoting B cell growth and differentiation. Interestingly, 
concentrations of BlyS have been associated with disease activity. Serum analysis of IPF 
patients has also shown increased concentrations of both non-organ specific as well as 
organ specific antibodies (Xue, Kass et al. 2013). Moreover, distinct HLA class II alleles 
are overrepresented in patients with IPF (Xue, Gochuico et al. 2011, Fingerlin, Zhang et 
al. 2016). 
These autoimmune features demonstrate high potential for novel specific, targeted 
therapies in IPF. Plasma exchange therapy, for instance, with subsequent elimination of 
autoantibodies, has led to an improved gas exchange in patients with acute exacerbations 
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of IPF (Donahoe, Valentine et al. 2015). In interstitial lung diseases associated with 
connective tissue disease (CTD-ILD), several studies have shown an improvement of 
functional lung parameters upon rituximab treatment (Bellan, Patrucco et al. 2020). 
Rituximab could also be a therapeutic option in IPF in particular and is currently being 
evaluated in a Phase II clinical trial (ClinicalTrials.gov; Identifier NCT01969409). 
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2 Objectives 
Soluble antibodies constitute the final effector molecules of adaptive immunity. Their 
effector functions are mediated by specific binding of antigen structures, which is strictly 
dependent on a functional three-dimensional structure attained in the endoplasmatic 
reticulum (ER) with the aid of the ER-resident protein folding machinery (Feige, 
Hendershot et al. 2010, Feige and Buchner 2014). Peptidyl-prolyl cis-trans isomerases 
(PPIases) represent an essential part of this machinery and catalyze important, rate 
limiting reactions in the process of antibody folding. Still, only two PPIases have been 
identified in this context, namely Cyclophilin B (CypB) (Meunier, Usherwood et al. 2002, 
Feige, Groscurth et al. 2009, Jansen, Määttänen et al. 2012, Lee, Choi et al. 2012) and 
FKBP1A (Lilie, Lang et al. 1993). 
Immunophilins represent a family of highly conserved PPIases. They can be classified 
into two main subfamilies, according to which immunosuppressive drug they 
preferentially bind to: Cyclophilins, binding to cyclosporin A (CsA), and FK506-binding 
proteins (FKBPs), binding to tacrolimus (also known as FK506) or rapamycin 
(Amaravadhi and Ho Sup 2016). Interestingly, FKBPs have not only been recognized as 
important factors within physiological processes such as protein folding or receptor 
signaling, but have also been linked to various diseases including cancer, cardiac diseases 
and neurodegenerative disorders (Bonner and Boulianne 2017). 
In idiopathic pulmonary fibrosis (IPF), a fibrotic lung disease involving autoimmune 
features, FKBP10 has been shown to be highly elevated and to promote disease 
progression (Staab-Weijnitz, Fernandez et al. 2015, Knüppel, Heinzelmann et al. 2018). 
Other FKBPs, however, have not been investigated in the context of IPF. Therefore, the 
former working group of Prof. Eickelberg has previously analyzed the expression of 
FKBP proteins in IPF using RNA microarray data from 99 IPF patients and 43 normal 
controls, identifying differential expression of four additional FKBPs, namely FKBP11, 
FKBP1A, FKBP5, and FKBP6 in IPF (Figure 10). Only FKBP11 and FKBP5 have had 
altered expression by more than 2-fold, which for FKBP5 could not be confirmed on 
protein level. Based on these findings, FKBP11 was chosen for further characterization. 
In particular, the following questions were addressed in this thesis:  
1. Are FKBP11 protein levels upregulated in another, independent IPF cohort? 
2. Which cell types express FKBP11 in IPF lung tissue and other human tissues? 
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3. How is FKBP11 regulated in the context of B cell to plasma cell differentiation? 
4. Which function does FKBP11 execute in plasma cells and how does it contribute 




Table 3: Instruments 
Device name Company 
-80°C freezer U570 HEF 
New Brunswick; Hamburg, 
Germany 
-20°C freezer MediLine Lgex 410 Liebherr; Biberach, Germany 
2100 Antigen Retriever 
Aptum Biologics; Southamptom, 
U.K. 
Analytical scale XS20S Dual Range Mettler Toledo; Gießen, Germany 
Autoclave DX-45 Systec; Wettenberg, Germany 
Autoclave VX-120 Systec; Wettenberg, Germany 
AxioImager M2 Zeiss; Jena, Germany 
BD LSR II Flow Cytometer 
Becton Dickinson; Heidelberg, 
Germany 
Cell culture work bench Herasafe KS180 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Centrifuge MiniSpin plus Eppendorf; Hamburg, Germany 
Centrifuge Rotina 420R Hettich; Tuttlingen, Germany 
Centrifuge with cooling, Micro200R Hettich; Tuttlingen, Germany 
CO2 cell incubator BBD6620 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Confocal microscope LSM 710 Zeiss; Jena, Germany 
Corning® LSETM Mini Microcentrifuge, 
120V 
Corning; Wiesbaden, Germany 
Coulter Q-Prep working station 
Beckman Coulter, München, 
Germany 
Cytospin™ 4 Cytocentrifuge 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Dry ice container Forma 8600 Series, 8701 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Electronic pipet filler Eppendorf; Hamburg, Germany 
Fridge MediLine LKv 3912 Liebherr; Biberach, Germany 
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Table 3: Instruments (continued) 
Device name Company 
Gel imagine system ChemiDoc XRS+ Biorad; Hercules, USA 
Gene Pulser MxcellTM Electroporation 
System 
Biorad; München, Germany 
Ice machine ZBE 110-35 Ziegra; Hannover, Germany 
Light Cycler LC480II 
Roche Diagnostic; Mannheim, 
Germany 
Liquid nitrogen cell tank BioSafe 420SC Cryotherm; Kirchen/Sieg, Germany 
Magnetic stirrer KMO 2 basic IKA; Staufen, Germany 
Mastercycler Nexus Eppendorf; Hamburg, Germany 
Microm HMS 740 Robot-Stainer 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Mikro-Dismembrator Sartorius, Göttingen, Germany 
Multipette stream Eppendorf; Hamburg, Germany 
Nalgene® Freezing Container Omnilab; Munich, Germany 
NanoDrop 1000 PeqLab; Erlangen, Germany 
Neubauer Chamber Celeromics; Grenoble, France 
pH meter InoLab pH 720 WTW; Weilheim, Germany 
Plate reader Sunrise Tecan; Crailsheim, Germany 
VWR® Tube Rotator and Rotisseries 
VWR International; Darmstadt, 
Germany 
Roll mixer 
VWR International; Darmstadt, 
Germany 
Power Supply Power Pac HC Biorad; Hercules, USA 
Scale XS400 2S Mettler Toledo; Gießen, Germany 
Shaker Duomax 1030 Heidolph; Schwabach, Germany 
Thermomixer compact Eppendorf; Hamburg, Germany 
Ultra-pure water supply MilliQ Advantage 
A10 




Table 3: Instruments (continued) 
Device name Company 
Vortex Mixer IKA; Staufen, Germany 
Vacuum pump NO22AN.18 with switch 2410 KNF; Freiburg, Germany 




3.2 Technical equipment 
Table 4: Technical equipment 
Product name Company 
24-well microplates  Ibidi; Planegg/Martinsried, Germany 
96-well imaging plates 
Corning, Thermo Fisher Scientific; 
Schwerte, Germany 
96-well microplates 
Berthold Technologies; Bad 
Wildbad, Germany 
Cell culture dishes 
Corning, Thermo Fisher Scientific; 
Schwerte, Germany 
Cell culture multi-well plates 
TPP Techno Plastic Producers; 
Trasadingen, Switzerland 
Cell scrapers 
Corning, Thermo Fisher Scientific; 
Schwerte, Germany 
Combitips advanced® Eppendorf; Hamburg, Germany 
Cryovials 1.5 ml 
Greiner Bio-One; Frickenhausen, 
Germany 
EDTA-coated vacutainer tubes Sarstedt; Nümbrecht, Germany 
FACS tubes 
BD Bioscience; Heidelberg, 
Germany 
Falcon tubes  
BD Bioscience; Heidelberg, 
Germany 
Filter tips 
Biozym Scientific; Hessisch 
Oldendorf, Germany 
Gene Pulser®/MicroPulserTM Electroporation 
cuvettes 
Biorad; München, Germany 
High binding ELISA plates COSTAR; New York, USA 
Measuring pipettes, sterile, single use  
VWR International; Darmstadt, 
Germany 
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Table 4: Technical equipment (continued) 
Product name Company 
Microscope slides 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Nylon filters, pore size 70 μm 
BD Bioscience; Heidelberg, 
Germany 
PCR plates, 96-well plate Kisker Biotech; Steinfurt, Germany 
Pipettes Research Plus Eppendorf; Hamburg, Germany 
Pipetting tips Eppendorf; Hamburg, Germany 
PVDF membranes 
Merck Millipore; Darmstadt, 
Germany 
Reaction tubes Eppendorf; Hamburg, Germany 
Reagent reservoirs Corning; New York, USA 
Sealing foils for PCR plates Kisker Biotech; Steinfurt, Germany 
Shandon™ Single Cytofunnel™ with White 
Filter Cards 
Thermo Fisher Scientific; Darmstadt, 
Germany 
Whatman blotting paper, 3 mm GE Healthcare; Freiburg, Germany 
 
3.3 Chemicals and reagents 
Table 5: Chemicals and reagents 
Chemical name Company 
3,3′,5,5′-Tetramethylbenzidine (TMB) 
substrate 
Sigma-Aldrich; St. Louis, USA 
8M Guanidine-HCl (GdnHCl) Solution 
ThermoFisher Scientific; Rockford, 
USA 
87% Glycerol AppliChem; Darmstadt, Germany 
Ammonium peroxodisulfate (APS) AppliChem; Darmstadt, Germany 
Antibody diluent Zytomed Systems; Berlin, Germany 
Bovine serum albumin (BSA) 
Sigma-Aldrich; Taufkirchen, 
Germany 




Table 5: Chemicals and reagents (continued) 
Chemical name Company 
Citrate Buffer, pH 6.0, 10×, Antigen Retriever 
Sigma-Aldrich; Taufkirchen, 
Germany 
Complete® Mini without EDTA (Protease-
inhibitor) 
Roche Diagnostics; Mannheim, 
Germany 




Thermo Fisher Scientific; Darmstadt, 
Germany 
Desoxyribonucleotides mix (dNTPs) 
Fermentas, Thermo Fisher Scientific; 
Schwerte, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
Dithiothreitol (DTT) AppliChem; Darmstadt, Germany  
ECL Plus Western Blotting Substrate 
Pierce, Thermo Fisher Scientific; 
Schwerte, Germany 
Ethanol AppliChem; Darmstadt, Germany 
Fetal bovine serum (FBS) GOLD, heat 
inactivated 
PAA, GE Healthcare; Freiburg, 
Germany 
Fluorescence mounting medium Dako; Hamburg, Germany 
Isopropanol AppliChem; Darmstadt, Germany 
Light Cycler 480 SybrGreen 1 Master Mix 
Roche Diagnostics; Mannheim, 
Germany 
Lipofectamine RNAiMAX 
Invitrogen, Life Technologies; 
Carlsbad, USA 
LymphoprepTM Axis-Shield; Oslo, Norway 
Methanol AppliChem; Darmstadt, Germany 
Methylthiazolyldiphenyl-tetrazolium bromide 
(MTT) 
Sigma-Aldrich; St. Louis, USA 
Non-essential Amino Acid Solution Sigma-Aldrich; St. Louis, USA 
Non-fat dried milk powder AppliChem; Darmstadt, Germany 
Paraformaldehyde (PFA) AppliChem; Darmstadt, Germany 
Penicillin-Streptomycin (100 U/ml) 
Gibco, Life Technologies; Carlsbad, 
USA 
PhosSTOP (Phosphatase-inhibitor) 




Table 5: Chemicals and reagents (continued) 
Chemical name Company 
Protein marker V Peqlab; Erlangen, Germany 
Random hexamers 
Applied Biosystems, Life 
Technologies; Carlsbad, USA 
Ready-to-use pNPP substrate for ELISA MABTECH; Nacka Strand, Sweden 
Restore Plus Western Blot Stripping Buffer 
Pierce, Thermo Fisher Scientific; 
Schwerte, Germany 
Sodium Bicarbonate (NaHCO3) Sigma-Aldrich; St. Louis, USA 
Sodium Carbonate (Na2CO3) Sigma-Aldrich; St. Louis, USA 
Sodium Pyruvate Life Technologies; Carlsbad, USA 
SuperSignal West Dura Chemiluminescent 
Duration Substrate 
Pierce, Thermo Fisher Scientific; 
Schwerte, Germany 
SuperSignal West Femto Chemiluminescent 
Duration Substrate 
Pierce, Thermo Fisher Scientific; 
Schwerte, Germany 




Tween 20 AppliChem; Darmstadt, Germany 
Tryptan Blue Solution (0.4%) 
Sigma-Aldrich; Taufkirchen, 
Germany 
UltraPure Dnase/Rnase-Free Distilled Water 






3.4 Cell culture 
3.4.1 Cell lines 
To create a better overview in the results section, hybridoma cell lines will be referred to 
as H1, H2 or H3 according to the following table. All cell lines represent suspension cell 
lines, apart from A549 which is adherent. 
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Table 6: Cell lines 








Kindly provided by Dr. Aloys 
Schepers, Monoclonal Antibody 
Core Facility, Helmholtz-
Zentrum München, Germany 
M6A8 (H2) Hybridoma Mouse 
Kindly provided by Dr. Aloys 
Schepers 
MEM-56 (H1) Hybridoma Mouse 
Kindly provided by Dr. Aloys 
Schepers 
MIS24C8 (H3) Hybridoma 
Mouse and 
rat 






Kindly provided by Prof. Edgar 





3.4.2 Cell culture media 
Table 7: Cell culture media 
Medium Company 
DMEM/F12 (1:1) 
Gibco, Life Technologies; Carlsbad, 
USA 
Opti-MEM I Reduced Serum Medium 
Gibco, Life Technologies; Carlsbad, 
USA 
Phosphate Buffered Saline (PBS), 1x 
Gibco, Life Technologies; Carlsbad, 
USA 
RPMI 1690, supplemented with L-Glutamine 
Gibco, Life Technologies; Carlsbad, 
USA 
 
3.5 Small interfering RNA (siRNA) 
All small interfering RNAs (siRNAs) were purchased as predesigned products from 
Ambion, Life Technologies, Carlsbad, USA. 
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Table 8: Small interfering RNA (siRNA). 
siRNA Species siRNA ID 
scrambled Silencer® Negative control 
No. 1 
None AM4611 
Silencer® Select FKBP11 siRNA Human s27898 
Silencer® Select FKBP11 siRNA Mouse and rat s82617 
Silencer® Select XBP1 siRNA Human 5533 
 
3.6 Kits 
Table 9: Kits 
Name Manufacturer 
GeneAmp PCR Kit 
Applied Biosystems, Life 
Technologies; Carlsbad, USA 
Human IgG ELISA development Kit MABTECH; Nacka Strand, Sweden 
Pierce BCA Protein Assay Kit Biochrom; Berlin, Germany 
Rneasy Mini Kit QIAGEN; Hilden, Germany 
Subcellular Protein Fractionation Kit for 
Cultured Cells 
Thermo Fisher Scientific; Darmstadt, 
Germany 
 
3.7 Cytokines, enzymes and inhibitors 
Table 10: Cytokines, enzymes and inhibitors 
Name Manufacturer 
0.25% Trypsin-EDTA solution 
Sigma-Aldrich; Taufkirchen, 
Germany 
Cyclosporin A (CsA) Sigma Aldrich; St. Louis, USA 
FK506 monohydrate (tacrolimus) Sigma Aldrich; St. Louis, USA 
IL-2 




Table 10: Cytokines, enzymes and inhibitors (continued) 
Name Manufacturer 
MuLV Reverse Transcriptase 
Applied Biosystems, Life 
Technologies; Carlsbad, USA 
R848 (Resiquimod) InvivoGen; San Diego, USA 
Ribonuclease A (Rnase) from bovine 
pancreas 
Sigma Aldrich; St. Louis, USA 
Rnase Inhibitor 
Applied Biosystems, Life 
Technologies; Carlsbad, USA 
Tunicamycin Sigma Aldrich; St. Louis, USA 
Trypsin from bovine pancreas Sigma Aldrich; St. Louis, USA 
 
3.8 Antibodies 
3.8.1 Antibodies for Western Blot 
Table 11: Primary antibodies for Western Blot 











Cell Signaling; Boston, 
USA 
Calreticulin 
Rabbit polyclonal anti- 
Calreticulin antibody 
1:1000 
















Cell Signaling; Boston, 
USA 
IgA 
Goat polyclonal anti 
human IgA 
1:500 
Sigma-Aldrich; St. Louis, 
USA 
IgG 






Goat polyclonal anti 
human IgM 
1:500 




Lamin A/C antibody 
1:1000 










Table 12: Secondary antibodies for Western Blot 

















GE Healthcare; Freiburg, 
Germany 
 
3.8.2 Antibodies for immunofluorescence stainings 
Table 13: Primary antibodies for immunofluorescence stainings 
Target Antibody Dilution Manufacturer 


























1:100 Atlas, Stockholm, Sweden 
IgA 
Goat polyclonal anti 
human IgA 
1:100 
Sigma-Aldrich, St. Louis, 
USA 
IgG 






Goat polyclonal anti 
human IgM 
1:100 







Table 14: Secondary antibodies for immunofluorescence stainings 
Target Antibody Dilution Manufacturer 
Goat IgG 
Alexa Fluor 488 Donkey 





Alexa Fluor 568 Donkey 





Alexa Fluor 488 Donkey 





Alexa Fluor 568 Donkey 





Alexa Fluor 488 Donkey 





Alexa Fluor 568 Donkey 





3.8.3 Antibodies for ELISA 
Antibody Species Dilution Manufacturer/Provider 
Anti-human IgG mAb 














Anti-mouse IgG (H/L); 
HRP conjugated 
Goat 1:1000 Biorad; Hercules, USA 
Monoclonal anti-fibrillin-1, 
Nr. 78 
Mouse See 4.3  





Oregon Health & Science 
University, Portland, USA 
 
3.8.4 Antibodies for flow cytometry 
All primary antibodies for flow cytometry were purchased from BioLegend, San Diego, 
USA and were used at a concentration of 5µl per 100µl of whole blood as recommended 
by the distributor. Appropriate isotype control antibodies were purchased from the same 
distributor and applied conforming to the concentrations of the primary antibodies. 
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Table 15: Antibodies for flow cytometry 
Target Fluorophore Clone Isotype 
CD3 APC/Cy7 HIT3a Mouse IgG2a, κ 
CD20 APC/Cy7 2H7 Mouse IgG2b, κ 
CD27 PE/Cy7 O323 Mouse IgG1, κ 
CD38 APC HB-7 Mouse IgG1, κ 
 
3.9 Primers for qRT-PCR 
All primers were synthesized by MWG Eurofins, Ebersberg, Germany. 
Table 16: Primer sequences 
Target Species Forward primer (5’-3’) Reverse primer (5’-3’) 
FKBP11 human GCAATCATTCCTTCTCACT AGTAGTTGGCTCGGATTAG 
Fkbp11 mouse ACTACACGGGCAGTTTGGTAG GCTCCAGACCTGGAATCACC 
MZB1 human ACTGGCAGGACTACGG AAGTAGTGCAAACATGTCCT 
PRDM1 human GGAACTTCTTGTGTGGTATT TCTGTGTTTGTGTGAGATTC 












Table 17: Software 
Software name Company 
Adobe Illustrator Adobe Inc.; San José, USA 
BD FACSDIVATM 
BD Biosciences; Heidelberg, 
Germany 
FlowJo Software TreeStart Inc.; Ashland, USA 
GraphPad Prism GraphPad Software; La Jolla, USA 
ImageJ 
National Institutes of Health; 
Bethesda, USA  
Image Lab Software Biorad; Hercules, USA 
LightCycler® 480 SW 
Roche Diagnostics; Mannheim, 
Germany 
Magelan Software Tecan; Crailsheim, Germany 
Microsoft Office Microsoft; Redmond, USA 
Tristar MicroWin 2000 
Berthold Technologies; Bad 
Wildbach, Germany 
ZEN 2010 – Digital Imaging for 
Lightmicroscopy Software 




4.1 Human materials 
4.1.1 Patient samples 
Patient lung tissue samples and blood specimen were obtained from two independent 
cohorts from the CPC-M bioArchive (Munich, Germany) and from the UGMLC Giessen 
Biobank (Giessen, Germany). Human material from the CPC-M bioArchive was 
authorized by the local ethics committee of Ludwig-Maximilians University of Munich, 
Germany (333-10). Likewise, human material from the UGMLC Giessen Biobank was 
approved by the Ethics Committee of the Justus-Liebig-University School of Medicine, 
Giessen, Germany (No. 31/93, 84/93, 29/01, 10/06, 111/08, and 58/15). Written informed 
consent was obtained from each subject. The tissue microarray (Multi-normal human 
tissues, 96 samples, 35 organs/sites from three individuals) was purchased commercially 
from Abcam, Cambridge, United Kingdom (ab178228). 
4.1.2 Gene expression data 
Preliminary data on FKBPs in normal histology control (n = 43) and IPF lung tissues (n 
= 99) were previously collected from the gene expression microarray data set generated 
on lung tissue samples obtained from the National Lung, Heart, and Blood Institute–
funded Tissue Resource Consortium, as described before (Yang, Pedersen et al. 2014, 
Bauer, Tedrow et al. 2015). Gene expression microarray data (Agilent Technologies, 
Santa Clara, CA), along with the associated clinical data, can be viewed on the Lung 
Genomics Research Consortium website (https://www.lung-genomics.org/research/) as 
well as on accession number GSE47460 or the Lung Tissue Research Consortium website 
(http://www.ltrcpublic.com). Significance was calculated using t statistics, while multiple 
testing was controlled by the false discovery rate method at 5% (Herazo-Maya, Noth et 
al. 2013). 
4.2 Cell culture experiments 
4.2.1 Cell culture conditions 
A549 cells were maintained in DMEM/F12 medium supplemented with 10% FBS and 
100 U/mL penicillin/streptomycin. For experiments, passages p3-p5 were used at a 
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confluency of 70-80%. RAJI, AG8 and the hybridoma cell lines (H1, H2 and H3) were 
cultured in RPMI 1690 medium supplemented with L-Glutamine, 10% FBS, 10mM 
Sodium Pyruvate, Non-essential Amino Acid Solution (1x) and 100 U/mL 
penicillin/streptomycin. Cells were grown at a density ranging from 2 x 105 – 9 x 105 
cells/ml and splitting was performed accordingly. Finally, peripheral blood mononuclear 
cells (PBMCs) were isolated from whole blood as shown below and cultured in the same 
manner as RAJI, AG8 and hybridoma cells. All cells were cultivated at 37°C in a direct 
heat CO2 incubator containing 5% CO2. All experiments were repeated at least three times 
to obtain independent biological replicates. 
4.2.2 Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from blood of healthy donors using density gradient centrifugation. 
For isolation, blood was drawn from healthy individuals and left in heparinized vials for 
a maximum of one hour at room temperature. Next, blood was mixed in equal parts with 
PBS and the mixture was carefully poured into a 50ml centrifugation tube containing 
15ml of LymphoprepTM density gradient medium. The vial was centrifuged for 20min at 
1080 g at 20°C without brake, resulting in the PBMCs being gathered in a single layer. 
PBMCs were then transferred to prewarmed medium and washed once using prewarmed 
medium. For this purpose, cells were spun down at 250 g at +4°C. Afterwards, PBMCs 
were seeded in a cell culture dish at a concentration of 1 x 106 cells/ml. 
4.2.3 Plasma cell differentiation of PBMCs 
Following isolation, PBMCs were seeded in a cell culture dish at a concentration of 1x106 
cells/ml and stimulated by 1000U/ml of recombinant IL-2 and 2.5µg/ml of the TLR 7+8 
ligand R848 (resiquimod), which is an established procedure to initiate plasma cell 
differentiation (Pinna, Corti et al. 2009, Laurent, Hoffmann et al. 2015). As a control, the 
same volumes of diluents were added to the PBMCs. After 7 days of incubation at 37°C, 
supernatants were collected to determine IgG concentration. An appropriate number of 
cells was used to produce cytospins. The remaining cells were harvested for RNA and 
protein isolation. 
4.2.4 Generation of cytospins 
To generate cytospins, 100µl of cell suspension (0.8 – 1.2 x 106 cells/ml) were transferred 
into a CytofunnelTM and spun down to a microscope slide at 300 RPM using a Cytospin™ 
Methodology 37 
4 Cytocentrifuge. The cytospins were allowed to dry overnight and the cells were fixed 
by application of 3.7% paraformaldehyde (PFA) in DPBS for 5min. 
4.2.5 MTT cytotoxicity assay 
To evaluate cell viability upon tunicamycin treatment or knockdown of FKBP11, 
methylthiazolyldiphenyl-tetrazolium bromide (MTT) was dissolved in PBS and added to 
the cultivated cells at a final concentration of 0.5mg/ml and incubated at 37°C for 30 min. 
For adherent cells, the supernatant was aspirated and crystals were solubilized in 0.5ml 
isopropanol/0.1% Triton X-100 for 30 min on a shaker at room temperature. Optical 
density was then measured at 570nm using the Sunrise multiplate reader. To estimate the 
percentage of viable cells, the optical density of the specimen was divided over the optical 
density received from a control not having received any intervention. For suspension 
cells, the procedure was similar with the exception that the cells were pelleted at 300 g 
prior to aspiration of the supernatant. 
4.2.6 Trypan Blue exclusion assay 
To estimate the number of viable cells, cell suspensions were mixed with equal volumes 
of Trypan Blue solution (1:10 in PBS) and transferred to a Neubauer chamber. Next, 
viable cells in four squares were manually counted, excluding blue cells. The number of 
cells per ml was then calculated using the following formula: 
Cells/ml = (Number of Cells x 10000) / (Number of squares x dilution) 
To determine the total number of cells, the calculated value was multiplied by the total 
volume of the cell suspension. 
4.2.7 Tunicamycin treatment of A549 and RAJI cells 
The artificial ER stress inducer tunicamycin was used to induce ER stress in A549 and 
RAJI cells. For tunicamycin treatment of A549 cells, see 4.2.8. For RAJI, cells were 
washed once in PBS and resuspended in starvation medium (RPMI 1640, 0.5% FBS) at 
a density of 3 x 105–5 x 105 cells/ml. Following 24 hours of starvation, cells were washed 
in PBS and resuspended in starvation medium containing different concentrations of 
tunicamycin (0.01mg/ml, 0.1µg/ml, 0.5µg/ml, 1µg/ml or 5µg/ml) or an equal volume of 
DMSO as a non-treated negative control. 24 hours later, cell viability was evaluated by 
an MTT cytotoxicity assay to rule out any relevant cell death due to tunicamycin 
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treatment. Expression of FKBP11 was then assessed on both protein and transcript levels. 
To verify successful induction of ER stress, expression of BiP was visualized using 
Western Blot analysis.  
4.2.8 SiRNA-mediated transfection of A549 cells 
For experiments involving A549 cells, knockdown was achieved using reverse 
transfection. First, transfection mixtures containing Opti-MEMTM I Reduced Serum 
Medium, Lipofectamine RNAiMAX and relevant siRNA (FKBP11 siRNA, XBP1 
siRNA) or negative control, scrambled siRNA (scr siRNA) were prepared and incubated 
for 20 minutes in 6-well plates. Next, A549 cells were detached using trypsin and 
resuspended in DMEM/F12 medium supplemented with 10% FBS. The resulting cell 
suspensions were transferred onto the prepared transfection mixtures. The final siRNA 
concentration was 10nM, and the cells were seeded at a density of 5 x 104–5.5 x 104 
cells/cm2. After an incubation time of 6–8 hours, A549 cells were starved overnight using 
starvation medium (DMEM/F12, 0.5% FBS) and treated with tunicamycin at different 
concentrations (0.01µg/ml, 0.1µg/ml, 1µg/ml) or equal volumes of DMSO as a negative 
control. After 24 hours, cell viability was assessed by Trypan blue exclusion assay and 
an MTT cytotoxicity assay. The remaining cells were used to isolate protein and RNA in 






Figure 7: Experimental setup of siRNA-mediated knockdown with subsequent tunicamycin 
treatment. 
Following knockdown and seeding of A549 cells for 24h, cells were starved for another 24h in 
starvation medium. Then, the tunicamycin treatment was initiated. After 24h of treatment, 
viability was assessed and the cells were harvested for further analysis. 
 
4.2.9 SiRNA-mediated transfection of the hybridoma cell line H3 
For the hybridoma cell line H3, transfection was attained by electroporation as shown 
before (Steinbrunn, Chatterjee et al. 2014). H3 cells at a density ranging from 3 x 105–5 
x 105 cells/ml were spun down at 300 g and resuspended in fresh RPMI 1640 medium 
without supplements at a concentration of 6 x 107 cells/ml. After addition of FKBP11 
siRNA (targeting both mouse and rat) at a concentration of 3µM or negative control, 
scrambled siRNA (scr siRNA) at the same concentration, 200µl of the mixture were 
transferred to a 2mm electroporation cuvette. Electroporation was then carried out with a 
Gene Pulser by application of a single exponential decay pulse at a capacity setting of 
960µF and a voltage of 250V. Subsequently, cells were transferred to prewarmed full 
medium, and stored at 37°C. After 48 hours, cell viability was assessed by Trypan blue 
exclusion assay and an MTT cytotoxicity assay. Moreover, supernatants were stored to 
determine levels of antibodies and the cells were harvested in order to review knockdown 
efficiency on both protein and transcript levels. 
4.3 Unfolding and refolding of immunoglobulin G 
Antibody refolding was essentially performed as described earlier (Lilie, Lang et al. 1993, 
Lilie 1997). A monoclonal, mouse anti fibrillin-1 antibody (Reinhardt, Keene et al. 1996) 
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was denaturated using a denaturation solution (3M Guanidine HCl, 0.1M Tris, 0.005M 
EDTA, pH 7.0) for 24h at an antibody concentration of 80µg/ml at 4°C. For initiation of 
refolding, the denaturated antibody solution was diluted under manual shaking by 10 fold 
in either PBS only, PBS containing a PPIase or PBS containing a control protein (RNase 
45µM) at 10°C, resulting in an antibody concentration of 8µg/ml. Recombinant PPIases 
used were either Cyclophilin B (5µM, positive control) or FKBP11 (45µM) (Ishikawa, 
Mizuno et al. 2017), both of which were kindly provided by Dr. Hans-Peter Bächinger 
(Department of Biochemistry and Molecular Biology, Oregon Health & Science 
University, Portland, USA). At given time points, aliquots of the refolding mixture were 
withdrawn and diluted under vigorous stiring by 12-fold in trypsinized milk (300U/ml 
Trypsin, 5% Milk, PBS) and kept on ice to stop further refolding. Final antibody 
concentrations were 0.66µg/ml. After completion of the final time point, the amount of 
correctly refolded antibody was determined by ELISA (see 4.4.1). The experimental 






Figure 8: Experimental setup of denaturation and subsequent refolding of IgG. 
Following denaturation with 3M GdnHCl, refolding was initiated by dilution (1:10) in either PBS, 
PBS containing RNase, or PBS containing a PPIase (CypB or FKBP11). At given time points, 
specimen were withdrawn, trypsinized and kept on ice to prevent further refolding. After 
collection of all specimen, an ELISA was performed to assess the yield of correctly refolded IgG 
in each withdrawn specimen. 
 
For experiments involving inhibition of PPIase activity, FKBP11 was preincubated for 1 
hour with either FK506 (180µM) or DMSO as a negative control at +10°C. As further 
negative controls, PBS was preincubated with either FK506 (180µM) or DMSO. 
Subsequently, antibody refolding was performed as described above. 
4.4 Immunological methods 
4.4.1 Enzyme-linked immunosorbent assay (ELISA) 
For determination of IgG concentrations in PBMC supernatants, a human IgG ELISA kit 
was utilized. A high binding ELISA plate was coated with MT145 antibody (in PBS) 
overnight. After washing once with PBS, blocking was performed for 1 hour with PBS-
Tween (0.05% Tween 20). Subsequently, PBMC supernatants acquired after 7 days of 
IL2/R848 treatment were incubated for 1 hour followed by a washing step. The secondary 
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antibody MT78-ALP, conjugated with alkaline phosphatase, was applied for 1 hour 
(diluted in PBS), and, posterior to washing 5 times, ready-to-use pNPP substrate for 
ELISA was instilled as an appropriate substrate for 20 minutes. Finally, optical density 
was measured at 405nm using a Sunrise multiplate reader and antibody concentration was 
calculated by comparison with a standard curve received with the lyophilized human IgG 
standard. 
To assess the rate of correctly refolded IgG, a high binding ELISA plate was coated with 
recombinantly expressed rf11 (Reinhardt, Keene et al. 1996), which was kindly provided 
by Dr. Hans-Peter Bächinger, diluted at a concetration of 5µg/ml in coating buffer 
(0.035M NaHCO3, 0.015M Na2CO3, pH 9.6), overnight. After washing one time with 
TBS-Tween (0.025% Tween 20), the coated wells were blocked with 5% milk in PBS for 
one hour. Then, aliquots from the refolding experiment were incubated for one hour. The 
plate was washed once, followed by one hour of incubation with an HRP-linked anti-
mouse antibody. After rinsing the plate 5 times, 3,3′,5,5′-Tetramethylbenzidine (TMB) 
substrate was incubated for 20 minutes and the signal was read at 650nm using a Sunrise 
multiplate reader. In the graphs, values shown represent the optical density measured at 
650nm minus blank values which were received by incubation with trypsinized milk 
without a primary antibody. 
4.4.2 Flow cytometry 
To assess the number of circulating plasma cells in blood of IPF patients in comparison 
with healthy donors, plasma cells from whole blood of IPF patients and healthy donors 
(all from the CPC-M bioArchive) were sorted using flow cytometry and identified as 
identified as CD20-/CD3-/CD27+/CD38+ cells (Figure 9). First, venous blood from IPF 
patients or healthy individuals was collected in EDTA-coated vacutainer tubes. For each 
staining, 100µl of blood were incubated with appropriate antibodies used to gate for 
plasma cells (Table 15) for 20 min at 4°C protected from light. In parallel, blood from the 
same specimen was stained with appropriate isotype controls. Next, lysis of erythrocytes 
was performed with a Coulter Q-Prep working station followed by data acquisition in a 
BD LSRII flow cytometer. FlowJo software was used for data analysis. Data was 
presented as ratios of CD3-/CD20-/CD27+/CD38+ cells to live cells. Negative thresholds 
for gating were set according to isotype-labelled controls. 
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Figure 9: Gating strategy for the detection of circulating plasma cells. 
Representative flow cytometry dot-plots of whole blood after red blood cell lysis. Cells were 
stained with a set of primary, monoclonal antibodies and gated for CD20-/CD3-/CD27+/CD38+ 
cells, which were characterized as circulating plasma cells. The gates were based on isotype-




4.4.3.1 Immunofluorescent stainings of tissue sections 
For deparaffinization and rehydration, paraffin-embedded sections were placed at 60°C 
for at least 30min, followed by tissue deparaffinization and hydration using a Microm 
HMS 740 Robot-Stainer according to the protocol described in Table 18. 
Table 18: Deparaffinization protocol 
Description Reagent Cycles Time 
Deparaffinization step Xylene 2x 5min 
Hydration step 
100% ethanol 2x 2min 
90% ethanol 1x 1min 
80% ethanol 1x 1min 
70% ethanol 1x 1min 
dH2O 1x 30sec 
 
After deparaffinization, slides were transferred into citrate buffer (1x, pH 6.0) and heated 
in a 2100 Antigen Retriever decloaking chamber for 30 seconds at 125°C, and 10 seconds 
at 90°C, in order to retrieve antigens. Subsequently, sections were allowed to cool down 
and placed into a blocking solution consisting of 5% BSA in Tris buffer (0.5M Tris, 1.5M 
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NaCl, pH 6.8) for 40 min to prevent nonspecific binding. Next, primary antibody 
solutions (Table 13) prepared in antibody diluent were applied to each tissue section for 
1 hour and washed three times in Tris buffer (5 min for each washing step). Slides were 
then incubated with secondary antibodies conjugated to appropriate fluorophores (Table 
14) and DAPI (1:1000) for 1 hour. Again, slides were rinsed three times in Tris buffer 
and covered with Flourescence Mounting Medium. For examination of the stainings, the 
Axio Imager Microscope was used.  
To quantify FKBP11+/CD38+ cells in IPF and donor sections, ten images sized 1.5mm2 
were randomly taken of each section. Then, FKBP11+/CD38+ cells were counted from 
each image, and the counted cells for all 10 images were added up. The person performing 
the cell counting was not informed about which sections belonged to IPF patients or 
control. 
4.4.3.2 Immunofluorescence stainings of cytospins 
All of the following steps were performed at room temperature. After generation and 
fixation of the cytospins (see 4.2.4), the cells were washed once with DPBS and 
permeabilized with 0.2% Triton X-100 in DPBS for 2 min to expose intracellular 
antigens. Next, cells were washed once in DPBS and blocking was performed for 1 hour 
using a blocking solution (5% BSA, 0.2% Tween, DPBS) to avoid unspecific binding. 
Primary antibodies prepared in blocking solution were then applied onto the cells for 1 
hour, followed by washing three times in DPBS. Subsequently, secondary antibodies 
conjugated to appropriate fluorophores and DAPI, both diluted in blocking solution, were 
incubated for 1 hour. Finally, the cytospins were cleansed three times with DPBS and 
covered with Flourescence Mounting Medium. The stainings were inspected using the 
Axio Imager Microscope or Confocal microscope LSM. 
4.4.4 Protein analysis 
4.4.4.1 Protein isolation 
To isolate protein from liquid nitrogen-frozen tissue, samples were homogenized using a 
Mikro-Dismembrator and taken up in Radio-Immunoprecipitation Assay (RIPA) buffer 
(50mM Tris HCl pH 7.4, 150mM NaCl, 1% Triton X100, 0.5% sodium deoxycholate, 
1mM EDTA, 0.1% SDS) containing a protease and a phosphatase inhibitor cocktail. The 
solution was then incubated for 30 min on ice, succeeded by short sonification and 
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centrifugation for 15 min at 13000 RPM at 4°C to clarify the lysates. Pellets were 
discarded and protein concentration was measured via Pierce BCA Protein Assay Kit 
following the manufacturer’s instructions. 
To receive protein from cultured cells, suspension cells were spun down at 300 g and 
pellets were incubated in RIPA buffer supplemented with a protease and a phosphatase 
inhibitor cocktail for at least 30 min on ice, followed by centrifugation at 15000 RPM at 
4°C. The pellets were discarded and protein concentrations determined as explained 
above. For adherent cells, the procedure was similar, with the difference that cells were 
detached using cells scrapers and taken up in RIPA buffer supplemented with a protease 
and a phosphatase inhibitor cocktail 
4.4.4.2 Subcellular fractionation of cultured cells 
To generate protein fractions based on their subcellular localization, a subcellular 
fractionation was performed using a Subcellular Protein Fractionation Kit for Cultured 
Cells. For adherent cell lines, cells were detached by 0.25% Trypsin-EDTA solution, 
centrifuged 5 min at 500 g and washed by resuspending the cell pellet in ice-cold PBS. 
Suspension cell lines were directly centrifuged for 5min at 500 g and washed in the same 
manner. The resulting cell suspensions were transferred to a 1.5ml centrifuge tube and 
centrifuged for 3 min at 500 g. The supernatants were discarded and the subcellular 
fractionation carried out according to the manufacturer’s instructions. 
4.4.4.3 SDS-Page and Western Blot analysis 
Following denaturation of protein samples by Laemmli buffer (65 mM Tris-HCl pH 6.8, 
10% Glycerol, 2% SDS, 0.01% bromophenol blue, 100mM DTT) at 95°C for 5-10min, 
proteins were concentrated on a 4 % SDS-PAGE Stacking gel and subsequently separated 
by size on a 10% SDS-PAGE Separation gel at 150V per gel for 90 min. The composition 





Table 19: Composition of 4% SDS-PAGE Stacking gel 
Reagent Volume 
Millipore-H2O 1.50ml 
0.5 M Tris-HCl pH 6.8 630µl 
10 % SDS 30µl 
Acrylamide/Bisacrylamide 330µl 
TEMED 2µl 
10% APS 13µl 
 
Table 20: Composition of 10% SDS-PAGE Separation gel 
Reagent Volume 
Millipore-H2O 3.61ml 
1.5 M Tris-HCl pH 6.8 2.25ml 
10 % SDS 90µl 
Acrylamide/Bisacrylamide 3ml 
TEMED 7.2µl 
10% APS 45µl 
 
After separation, immunoblotting of the protein to a methanol-activated polyvinylidene 
difluoride (PVDF) membrane was performed at 240mA per gel for 90 min. To prevent 
non-specific binding, the membrane was blocked with 5% milk in TBS-T (0.1% Tween 
20, TBS). This was succeeded by overnight application of primary antibodies (Table 11) 
at 4°C. After washing the membrane in TBS-T for three times, the membrane was 
incubated with an appropriate secondary antibody (Table 12) for 1 hour at room 
temperature. Again, the membrane was washed three times, and proteins were visualized 
with the Gel imagine system ChemiDoc XRS+ after application of a suitable substrate 
(SuperSignalTM West Dura Extended Duration Substrate or SuperSignalTM West Femto 
Maximum Sensitivity Substrate). Detected bands were quantified using Image Lab 
software or ImageJ software and relative protein abundance was calculated by dividing 
the band intensity of the target protein over the loading control (ACTB) of the same 
sample. 
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4.5 Molecular biological methods 
4.5.1 RNA expression analysis 
4.5.1.1 RNA isolation 
For isolation of RNA from cell cultures, the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) was used. For suspension cell cultures, cells were spun down at 300 g and the 
pellet was resuspended in the lysis buffer provided with the kit. Then, the instructions 
provided with the kit were followed. After isolation, total RNA was eluted in 35μl of 
DNase/RNase-free dH2O and the concentration determined at a wavelength of 260nm 
using NanoDrop 1000. 
For adherent cells, the procedure was similar with the difference that instead of 
centrifugation, the cells were detached using a cell scraper and diluted in lysis buffer. 
4.5.1.2 cDNA synthesis by Reverse Transcription 
Following isolation, 1µg of RNA was diluted in 20µl of DNase/RNase-free dH2O and 
denatured using an Eppendorf Mastercycler according to the following settings: 
lid=45°C, 70°C for 10 min and 4°C for 5 min. After denaturation, reagents provided with 
the GeneAmp PCR kit were added as shown in Table 21, followed by reverse 
transcription using an Eppendorf Mastercycler (settings: lid=105°C, 20°C for 10 min, 
42°C for 60 min and 99°C for 5 min). Finally, the resulting cDNA was diluted at a ratio 
of 1:4 with DNase/RNase-free dH2O. 
Table 21: Mastermix for cDNA synthesis 
Reagent Stock concentration Final concentration (40µl) Final volume (µl) 
10x PCR Buffer II 10x 1x 4 
MgCl2 solution 25mM 5mM 8 
PCR Nucleotide Mix (dNTP)  
 
10mM 1mM 4 
Random Hexamers 
 
50µM 2.5µM 2 
RNase Inhibitor  
 
20u/µl 1u/µl 2 
MuLV Reverse Transcriptase 50u/µl 2.5u/µl 2 
Denaturated RNA - - 18 
Total volume of the master mix 40 
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4.5.1.3 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
To determine relative transcript abundance of a specific gene, quantitative real-time PCR 
(qRT-PCR) was performed using SYBR Green PCR master mix and primer mixtures 
(Table 16) with a LightCycler® 480II. The exact composition of reaction mixes is shown 
in Table 22. The protocol set for the qRT-PCR reaction is summarized below. 
Denaturation, annealing and elongation were repeated in 45 cycles. Results were 
indicated as “-ΔCp” values (-ΔCp=Cpreference–Cptarget). For standardization of relative 
mRNA expression, GAPDH was employed as an endogenous control. 
Table 22: qPCR reaction mix 
Reagent Stock concentration Final concentration Final volume (µl) 
DNase/RNase-free H2O - - 1 
SYBR Green PCR master mix 2x 1x 5 
Forward/Reverse Primer Mix 10µM each 0.5µM each 2 
cDNA 6.25ng/µl 12.5ng/µl 2 
Total volume of reaction mix 10 
 
Cycle step Temperature Duration 
Initial denaturation 95°C 5min 
Denaturarion 95°C 5sec 
Annealing 59°C 5sec                         45 cycles 
Elongation 72°C 20sec 
Melting curve 60-95°C 1min 
Cooling down 4°C On hold 
 
4.5.2 SiRNA-mediated transfections 
For siRNA-mediated transfections, see 4.2.8 and 4.2.9. 
4.6 Statistical analysis 
Statistical analysis was performed using GraphPad PRISM 5. Data are presented as mean 
and standard error of the mean (SEM). Each experiment was performed at least three 
times. Paired data were analyzed by a paired t-test if not indicated otherwise. For unpaired 
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data, a two-tailed Mann-Whitney was used if not indicated otherwise. A p-value < 0.05 
was considered significant. More details on the statistical analysis and on the number of 
replicates can be found in the associated figure legends. 
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5 Results 
5.1 FKBP11 is highly increased in IPF lung tissues 
FKBP proteins fulfil versatile functions in different cell types and have been reported to 
be involved in various pathologies. In IPF, FKBP10 was previously shown to be increased 
in IFP lung tissues and to contribute towards the progression of the disease (Staab-
Weijnitz, Fernandez et al. 2015, Knüppel, Heinzelmann et al. 2018). 
To assess a potential impact of other FKBP proteins on IPF, the working team of Prof. 
Eickelberg has formerly analyzed differential expression of FKBP proteins within a 
microarray dataset consisting of 43 healthy control samples and 99 IPF samples (Bauer, 
Tedrow et al. 2015). With a false discovery rate of 5%, and a fold change cut off of 2.0, 
FKBP11 (fold change: +2.2) and FKBP5 (fold change: -3.4) were the most differentially 
expressed FKBP proteins (fold change: +2.2). Interestingly, FKBP11 was more 
upregulated than FKBP10 (fold change: +1.7), and thus the most upregulated FKBP 








Figure 10: Differential expression of FKBP proteins in IPF lungs (preliminary data). 
FKBP gene expression data was extracted from microarray data of normal histology controls (n 
= 43) and samples from IPF patients (n = 99) and presented in a Box- and whisker plot. With a 
false discovery rate of 5% and a fold change cut-off of 2.0, FKBP11 and FKBP5 were the most 
differentially expressed FKBP proteins, with FKBP11 being the most upregulated (fold change 
of +2.2). With a fold change of +1.7, FKBP10 expression was also significantly increased in 
agreement with previous reports (Staab-Weijnitz, Fernandez et al. 2015, Knüppel, Heinzelmann 
et al. 2018). Results are shown as mean of relative FKBP transcript abundance and error bars 
represent SEM. Significance was calculated using t statistics (p-values indicated in red), and 
multiple testing was controlled by the false discovery rate method at 5% (Herazo-Maya et al., 
2013). 
 
To verify these findings, protein expression of FKBP5 and FKBP11 was assessed in total 
lung tissue homogenates of two independent IPF cohorts. While protein levels of FKBP5 
did not differ significantly from healthy control lungs (preliminary data, not shown), 
protein levels of FKBP11 were highly increased in IPF (Figure 11). 
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Figure 11: FKBP11 is upregulated in lung tissues of IPF patients. 
Western Blot analysis of FKBP11 was performed from whole lung tissue homogenates from 
donor samples (ctrl) and patients with IPF. Samples were obtained from the UGMLC Giessen 
Biobank (donor: n=5, IPF: n=8). FKBP11 was significantly upregulated in IPF tissues as 
compared to donor tissues (ctrl). Results are shown as mean of Western Blot densitometry 
(relative units, normalized to ACTB) and error bars represent SEM. A two-tailed Mann-Whitney 
test was used for statistical analysis (*p<0.05). ACTB = β-actin as loading control. 
 
5.2 FKBP11 is identified in CD27+/CD38+/CD138+/CD3-/CD20-/CD45- 
plasma cells in IPF lungs 
In order to further characterize expression of FKBP11 in IPF lungs, immunofluorescent 
stainings of IPF lung tissue sections were performed using different markers of the 
hematopoietic lineage. 
5.2.1 FKBP11 is identified in CD27+/CD38+/CD138+/CD3-/CD20-/CD45- plasma 
cells in IPF lungs. 
In immunofluorescent stainings, FKBP11 was exclusively expressed by 
CD27+/CD38+/CD138+/CD3-/CD20-/CD45- cells in IPF lungs (Figure 12A and B). 
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This set of markers is typical of plasma cells (Tellier and Nutt 2017). In contrast, FKBP11 
was not identified in CD20+ and CD45+ cells (Figure 12B), being typical of naïve B cells 
(Pagel, Hedin et al. 2003), and neither in CD3+ cells (Figure 12B), marking T cells 
(Clevers, Alarcon et al. 1988). Moreover, FKBP11 was also found to be expressed in 
CD38+ plasma cells in lymphatic tissues of the body, such as spleen, tonsils, small 
intestine and thymus, by using immunofluorescence of a tissue microarray (Figure 12C). 





Figure 12: FKBP11 is identified in CD27+/CD38+/CD138+/CD3-/CD20-/CD45- plasma 
cells. 
Immunofluorescent stainings with different markers of the hematopoietic lineage in IPF lung 
tissue sections obtained from the CPC-M bioArchive (A and B) and a commercially acquired 
tissue microarray (C) were carried out.  In tissue sections from IPF patients, FKBP11 was 
identified in CD27+/CD38+/CD138+/CD3-/CD20-/CD45- cells (A and B). Using a tissue 
microarray, FKBP11+/CD38+ cells were found in other lymphatic tissues of the body (C), namely 
spleen, tonsils, small intestine and thymus. For each staining, one representative image is shown. 




5.2.2 IPF lungs show an elevated number of plasma cells as compared to donor 
lungs 
In consistency with the increase of FKBP11 in lung tissue homogenates of IPF patients 
shown in Figure 11, the number of plasma cells in immunofluorescent stainings of IPF 
tissue sections was drastically increased as compared to control sections (Figure 13A and 
B). This suggests the cause of the elevated FKBP11 levels to be an elevated number of 
plasma cells. In contrast, using FACS analysis on peripheral blood, no significant increase 
in circulating plasma cells was detected (Figure 13C). Plasma cells were gated as CD3-
/CD20-/CD27+/CD38+ cells and displayed in proportion to all living cells (for further 
details and gating strategy see 4.4.2 and Figure 9). This suggests that plasma cells in IPF 





Figure 13: Plasma cells are highly elevated in IPF lungs. 
FKBP11+/CD38+ cells were counted in immunofluorescent stainings of control (ctrl, n=5) and 
IPF (n=3) lung tissue sections from the CPC-M bioArchive. For each section, 10 random images 
of 1.5mm2 were taken and cells counted in each image were added (B). Representative images 
are shown in (A). To determine the numbers of circulating plasma cells, blood from healthy 
controls (n=20) and IPF patients (n=13) from the CPC-M bioArchive was sorted for CD3-/CD20-
/CD27+/CD38+ cells using flow cytometry (C). In IPF tissue sections, FKBP11+/CD38+ cells 
were highly elevated as compared to control (B). In peripheral blood, the number of circulating 
plasma cells was unchanged (C). Results are shown as mean of FKBP11+ cells counts or ratios 
of CD3-/CD20-/CD27+/CD38+ cells to live cells and error bars represent SEM. For statistical 
analysis, a two-tailed Mann-Whitney test was used (*p<0.05). Scale bar: 50µm. 
 
5.2.3 FKBP11 is expressed by CD38- secretory cells 
Utilizing the same tissue microarray as in 5.2.1, expression of FKBP11 was analyzed in 
several different body tissues. Besides plasma cells (CD38+), secretory cells from the 
pancreas and stomach (both CD38-) showed expression of FKBP11 (Figure 14A). This 
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is consistent with previous findings suggesting a role of FKBP11 in secretory tissues 
(Rulten, Kinloch et al. 2006). 
Contrarily, other tissues from the tissue microarray, for instance, lung and muscle tissue, 
did not show expression of either FKBP11 or CD38 (Figure 14B). 
 
Figure 14: FKBP11 is expressed by CD38- secretory cells in the pancreas and stomach. 
A human tissue microarray was stained for FKBP11 and CD38 (also used in Figure 12C). 
FKBP11+/CD38+ cells are shown in Figure 12C. Pancreas and stomach showed non-plasma 
(CD38-), FKBP11+ cells (A). The remaining tissues on the tissue microarray, for instance, muscle 
and lung, did not show expression of FKBP11 (B). Each tissue on the microarray contained tissues 
from three individual, healthy donors (n=3), and one representative image is shown. Scale bar: 
50µm. 
 
5.3 In vitro plasma cell differentiation leads to an upregulation of FKBP11. 
Given the specific expression of FKBP11 in plasma cells (Figure 12A and C), but not in 
naïve B cells (Figure 12B), it was hypothesized that FKBP11 is upregulated within the 
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process of B cell to plasma cell differentiation. To evaluate this, PBMCs from healthy 
donors were isolated and treated with a combination of IL2 and R848 (resiquimod) for 7 
days. This treatment has previously been shown to result in selective activation of 
memory B cells into antibody producing plasma cells (Pinna, Corti et al. 2009, Laurent, 
Hoffmann et al. 2015). 
5.3.1 IL2/R848 treatment induces plasma cell differentiation 
Isolation of PBMCs and subsequent 7-day treatment with a combination of IL2 and R848 
lead to an elevated concentration of IgG within cell culture supernatants as compared to 
vehicle control (Figure 15A). Moreover, cytospins stained for IgG following 7-day 
treatment showed an elevated number of IgG+ cells (Figure 15B), suggesting that plasma 
cell differentiation occurred. This was verified by determination of two established 
markers of B cell activation, namely PRDM-1 (Shaffer, Lin et al. 2002) and MZB1 
(Schiller, Mayr et al. 2017). Both markers were significantly increased (Figure 15C). 
Finally, upregulation of BiP (also HSPA5, GRP78) affirmed promotion of the UPR as an 
important part of plasma cell differentiation (Figure 16B). 
Results 59 
 
Figure 15: IL2/R848 treatment induces plasma cell differentiation. 
PBMCs were isolated from blood of three individual, healthy donors (n=3) and treated with a 
combination of IL2 and R848 or vehicle control (ctrl). Following IL2/R848 treatment, IgG levels 
in the supernatants were elevated in comparison to control in absolute and relative numbers (A), 
and cytospins showed IgG positive PBMCs (B). At the same time, transcript levels of the plasma 
cell differentiation markers MZB1 and PRDM1 were increased (C). Results are shown as mean 
of relative IgG production or transcript levels (normalized to GAPDH) and error bars represent 
SEM. A paired t-test was used for statistical analysis (*p<0.05). Scale bar: 200µm. 
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5.3.2 Plasma cell differentiation induces FKBP11 
Determination of FKBP11 in PBMCs treated with IL2/R848 showed a significant 
elevation of FBKP11 on both transcript (Figure 16A) and protein levels (Figure 16B), 
indicating that FKBP11 is upregulated within the process of B cell to plasma cell 
differentiation. 
 
Figure 16: Plasma cell differentiation induces FKBP11. 
Following IL2/R848 treatment of PBMCs (Figure 15), transcript and protein levels of FKBP11 
were determined. Following treatment, FKBP11 was elevated in comparison to control (ctrl) on 
both trancript (A) and protein (B) levels. Upregulation of BiP indicated induction of the UPR as 
a part of plasma cell differentiation (B). The experiment was performed using PBMCs from three 
individual, healthy donors (n=3). Results are shown as mean of transcript levels (normalized to 
GAPDH) and error bars represent SEM. A paired t-test was used for statistical analysis (*p<0.05). 
ACTB = β-actin as loading control. 
 
5.4 FKBP11 is upregulated upon ER stress in an XBP1-dependent manner 
For plasma cell differentiation, B cells require to upregulate the unfolded protein response 
(UPR) in preparation for high rates of antibody production (Tellier and Nutt 2018). The 
UPR, again, is induced by accumulation of unfolded proteins resulting in ER stress. 
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Moreover, FKBP11 has been characterized as an ER-resident peptidyl prolyl isomerase 
(PPIase) (Ishikawa, Mizuno et al. 2017). 
Based on these considerations, regulation of FKBP11 upon ER stress was analyzed by 
induction of ER stress using tunicamycin, an artificial inducer of ER stress (Bassik and 
Kampmann 2011). Subsequently, subcellular fractionation was performed to detect 
subcellular localization of FKBP11 in tunicamycin treated cells. The experiments were 
performed in two different cell lines, namely A549 (derived from lung adenocarcinoma) 
and RAJI (derived from Burkitt’s lymphoma). 
5.4.1 FKBP11 is upregulated upon ER stress 
24h-treatment of A549 and RAJI cells with tunicamycin lead to an induction of ER stress 
as indicated by upregulation of BiP (Figure 17). At the same time, tunicamycin treatment 
lead to upregulation of FKBP11 in a dose dependent manner in both cell lines (Figure 
17), suggesting regulation of FKBP11 by ER stress. 
 
Figure 17: FKBP11 is upregulated upon ER stress. 
A549 (from lung adenocarcinoma) and RAJI cells (from Burkitt‘s lymphoma) were treated with 
increasing concentrations of tunicamycin to induce ER stress. Upon tunicamycin treatment, 
FKBP11 was elevated in both A549 (A) and RAJI (B) cells in a dose dependent manner in 
comparison to vehicle control. Upregulation of BiP confirmed induction of the UPR (A and B). 
The experiment was performed three times under the same conditions (n=3), and one 
representative Western Blot was shown for each cell line. ACTB = β-actin as loading control. 
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5.4.2 FKBP11 localizes to the ER 
Given that a concentration of 0.1µg/ml tunicamycin was sufficient for induction of ER 
stress (Figure 17), this concentration was used for the subsequent experiments. 
Subcellular fractionation of tunicamycin treated cells displayed predominance of 
FKBP11 in the microsomal fraction in both A549 and RAJI cells (Figure 18). This pattern 
was also observed for Protein disulfide-isomerase 3 (PDI3), a known ER resident protein 
(Bottomley, Batten et al. 2001). In consistency with previous findings indicating ER 
residency of FKBP11 (Ishikawa, Mizuno et al. 2017), these results confirm ER residency 
of FKBP11. 
 
Figure 18: FKBP11 localizes to the ER. 
Following tunicamycin treatment (0.1µg/ml) of A549 and RAJI cells (Figure 8), subcellular 
fractionation was performed. Subcellular fractionation showed a similar enrichment pattern for 
FKBP11 as for the ER-resident Protein disulfide-isomerase 3 (PDIA3), with main localization in 
the microsomal (ME) and the nuclear extract (NE), but no detection in the cytosolic extract (CE) 
and in the chromatin-bound extract (CB). 
 
5.4.3 XBP1 mediates upregulation of FKBP11 in ER stress 
ER stress is mediated by different pathways inducing distinct transcription factors, 
including XBP1, ATF4 and ATF6 (Hetz 2012). XBP1, in particular, has been ascribed as 
an essential factor in plasma cell differentiation and as an important transcription factor 
of protein folding catalysts within plasma cells (Iwakoshi, Lee et al. 2003). Therefore, 
siRNA silencing experiments were conducted in order to clarify if FKBP11 is regulated 
depending on XBP1. 
In fact, A549 cells with prior silencing of XBP1 using siRNA showed nearly no 
upregulation of FKBP11 upon ER stress induced by tunicamycin, as compared to scr 
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(scrambled) siRNA control (Figure 19B and C). The effective silencing was affirmed on 
transcript levels (Figure 19A). Taken together, these findings suggest a regulation of 
FKBP11 by ER stress in an XBP1 dependent manner. 
 
Figure 19: XBP1 mediates upregulation of FKBP11 in ER stress. 
A549 cells were transcfected using lipofectamine with XBP1 siRNA for XBP1 knockdown or 
scramled (scr) siRNA for control and subsequently treated with tunicamycin (0.1µg/ml) for ER 
stress induction. Transfection with XBP1 siRNA led to knockdown of XBP1 as assessed by qPCR 
(A, normalized to GAPDH). Following tunicamycin treatment, cells with knockdown of XBP1 
did not upregulate FKBP11, as compared to control (scr) showing a clear upregulation of FKBP11 
(B,C). The experiment was performed five times under the same conditions (n=5), and one 
representative Western Blot is shown. Results are shown as mean of transcription levels 
(normalized to GAPDH) or Western Blot densitometry (relative units, normalized to ACTB) and 
error bars represent SEM. A paired t-test was used for statistical analysis (*p<0.05, **p<0.01). 
ACTB = β-actin as loading control. 
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5.4.4 FKBP11 protects from ER stress induced cell death 
To assess the importance of FKBP11 within the unfolded protein response, the effect of 
siRNA silencing of FKBP11 under the conditions of ER stress was assessed. Upon 
treatment with tunicamycin, A549 cells with prior siRNA silencing of FKBP11 showed 
a higher susceptibility towards ER stress mediated cell death as compared to scr siRNA 
control (Figure 20A). This argues for a protective role of FKBP11 under conditions of 
ER stress. 
 
Figure 20: FKBP11 protects from ER stress induced cell death. 
A549 cells were transcfected using lipofectamine with FKBP11 siRNA for FKBP11 knockdown 
or scramled (scr) siRNA for control and subsequently treated with increasing concentrations of 
tunicamycin for ER stress induction. Transfection with FKBP11 siRNA led to knockdown of 
FKBP11 as assessed by Western Blot (B, tunicamycin concentration used: 0.1µg/ml). Following 
tunicamycin treatment, cells with prior knockdown of FKBP11 (FKBP11 siRNA) showed a 
decreased viability as compared to control (scr siRNA) in trypan blue exclusion (A). The 
experiment was performed three times under the same conditions (n=3), and one representative 
Western Blot is shown. Results are shown as mean of percentage of viable cells and error bars 
represent SEM. A paired t-test was used for statistical analysis (*p<0.05 **, p<0.01). ACTB = β-
actin as loading control. 
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5.5 FKBP11 is a capable antibody folding catalyst 
After assessing expression and regulation of FKBP11, the function of FKBP11 was 
finally to be analyzed. As FKBP11 was specifically expressed by plasma cells (Figure 12 
and Figure 13), and upregulated within the process of B cell to plasma cell differentiation 
(Figure 16), it was hypothesized that FKBP11 is directly involved in the process of 
antibody production within plasma cells. 
5.5.1 FKBP11 is highly expressed in antibody producing hybridoma cell lines 
Hybridoma cell lines are used for the production of large amounts of monoclonal 
antibodies. A hybrid cell line is formed after fusion of antibody producing splenocytes 
from immunized mice or rats and an immortalized B cell line, a myeloma. As a 
consequence, the hybridoma combines the capability of antibody production from the 
antibody producing splenocytes, as well as the longevity and reproductivity from the 
myeloma (Nelson, Reynolds et al. 2000). 
Protein extracts from three antibody producing rat hybridomas (H1-H3) showed high 
expression of FKBP11 as compared to control (Figure 21A). The mouse myeloma cell 
line P3X63-Ag8.653 (AG8), which was utilized for fusion of the hybridomas, was used 
as a control. As expected, AG8, as a non-antibody producing cell line, did not show 
expression of IgG within the protein extracts as compared to the hybridomas (Figure 
21A). 
Moreover, subcellular fractionation of H3 displayed an equivalent enrichment pattern as 
Calreticulin (Figure 21B), another marker of the ER (Michalak, Groenendyk et al. 2009). 
Using confocal microscopy of H3, colocalization of FKBP11 and Concanavalin A, a 
marker of the ER (Herman and Shannon 1984), was illustrated (Figure 21C), confirming 
ER residency of FKBP11 in antibody producing cells. 
Taken together, these results support a role of FKBP11 in antibody producing cells. 
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Figure 21: FKBP11 is highly expressed in antibody producing hybridoma cell lines. 
Expression of FKBP11 was assessed in antibody producing rat/mouse hybridoma cell lines (H1-
H3) using Western Blot analysis (A), and subcellular localization of FKBP11 was determined 
using subcellular fractionation (B) and confocal microscopy of a cytospin of H3 (C). Protein 
extracts from three different rat/mouse hybridoma cell lines showed elevated levels of FKBP11 
and IgG, as compared to the control mouse myeloma cell line P3X63-Ag8.653(AG8) used for 
fusion of the hybridomas (A). Subcellular fractionation showed a similar enrichment pattern for 
FKBP11 as for the ER-resident protein calreticulin (CALR), with main localization in the 
microsomal (ME) and the nuclear extract (NE), but no detection in the cytosolic (CE) and 
chromatin-bound (CB) extract (B). Confocal microscopy of a cytospin of H3 displayed 
colocalization of FKBP11 with Concanavalin A (ConA), a known ER marker (C). ACTB = β-
actin as loading control. Scale bar: 20µm. 
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5.5.2 Silencing of FKBP11 results in depressed antibody production 
Given the high levels of FKBP11 and IgG in protein extracts (Figure 21A), H3 was 
chosen for loss of function experiments to further characterize the function of FKBP11. 
Silencing of FKBP11 was performed using electroporation and subsequent delivery of 
FKBP11-specific siRNA, resulting in an average knockdown efficiency of 67% (Figure 
22A and B). 
After 24h, supernatants were immunoblotted and stained for rat IgG, showing 
significantly less IgG heavy chains (IgH) in supernatants of cells with prior silencing of 
FKBP11 as compared to scr siRNA control (Figure 22A and C). This further supports a 
function of FKBP11 in antibody production. 
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Figure 22: Knockdown of FKBP11 results in depressed antibody production. 
The hybridoma cell line H3 (Figure 21) was electroporated and subsequently transcfected with 
FKBP11 siRNA for FKBP11 knockdown or scramled siRNA (scr) for control. Transfection with 
FKBP11 siRNA led to knockdown of FKBP11 as assessed by Western Blot (A, B), with an 
average knockdown efficiency of 67 ± 16%. Knockdown of FKBP11 resulted in less secreted 
antibodies, as assessed by Western blot analysis of IgG heavy chains (IgH) in the cell culture 
supernatants (A, C). The experiment was performed four times under the same conditions (n=4), 
and one representative Western Blot is shown. Results are shown as mean of Western Blot 
densitometry (relative units, normalized to ACTB) and error bars represent SEM. A paired t-test 
was used for statistical analysis (*p<0.05 **, p<0.01). ACTB = β-actin as loading control. 
 
5.5.3 FKBP11 is capable of antibody folding in vitro 
To finally address the hypothesis of FKBP11 functioning as an antibody foldase, an in 
vitro antibody refolding assay was used. In this assay, IgG was fully denaturated using 
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guanidine hydrochloride (GdnHCl). Following denaturation, refolding kinetics in 
absence and presence of the purified, recombinant FKBP domain of FKBP11(amino acids 
Gly28-Ala146, as described in (Ishikawa, Mizuno et al. 2017)) were monitored by an IgG 
ELISA. The readouts of the ELISA indicated the amount of correctly refolded IgG only, 
for the reason that antigen-antibody binding is strictly dependent on the native three-
dimensional structure of the IgG (Lilie, Lang et al. 1993, Lilie 1997). As negative 
controls, a vehicle control (PBS) and another protein (RNase) were used. As a positive 
control, CypB, a commonly known antibody folding PPIase (Feige, Hendershot et al. 
2010), was used. 
Addition of the purified, recombinant FKBP domain of FKBP11 to the refolding of 
denatured IgG resulted in an increase of both the rate of refolding and the total yield of 
correctly refolded IgG as compared to negative controls (Figure 23A). Compared to 
CypB, however, considerably higher concentrations of FKBP11 (45µM of FKBP11 in 
comparison to 5µM of CypB) were required to demonstrate similar effects on refolding 
activity (Figure 23A). 
Prior incubation of the purified, recombinant FKBP domain of FKBP11 with tacrolimus 
(FK506) inhibited the effects of FKBP11 on antibody folding as compared to prior 
incubation with vehicle control (DMSO) (Figure 23B). Tacrolimus is a known inhibitor 
of many FKBP proteins, due to its ability to bind the PPIase activity-bearing FKBP 
domain (Kay 1996). 
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Figure 23: FKBP11 is capable of antibody folding in vitro. 
Whole IgG was denatured using guanidine hydrochloride (GdnHCl). After denaturation, 
refolding was initiated by dilution with either pure PBS (vehicle control), 45µM of RNase 
(negative control, diluted in PBS), 5µM of recombinant Cyclophilin B (CypB, positive control, 
diluted in PBS) or 45µM of the recombinant FKBP domain of FKBP11 (diluted in PBS). For the 
refolding experiments, the purified FKBP domain of FKBP11 (amino acids G28 - A146) without 
the N-terminal signal peptide and the C-terminal transmembrane region was used. Dilution with 
FKBP11 resulted in an increase of both refolding speed and total yield of refolded IgG as 
compared to negative controls (PBS, Rnase) (A). In contrast with the positive control (CypB), 
higher concentrations of FKBP11 were required to demonstrate a similar effect on refolding 
(45µM of FKBP11 by contrast with 5µM of CypB) (B). The effects of FKBP11 were inhibited 
by prior incubation with tacrolimus (FK506) (C). The experiment was performed three times 
under the same conditions (n=3). Results are shown as mean of absorbance minus blank values, 
and error bars represent SEM. 
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5.6 Antibody yields are elevated in IPF 
Given increased levels of FKBP11 in IPF lung tissues (Figure 11), and the function of 
FKBP11 in antibody folding (Figure 23), it was assumed that antibody levels in IFP lung 
tissues are increased. To assess this, immunoblots of IPF lungs tissues were stained for 
the antibody isotypes IgG, IgA and IgM. Moreover, immunofluorescent stainings were 
performed to evaluate colocalization of FKBP11 with the antibody isotypes IgG, IgA and 
IgM. 
IPF lung tissue samples from MLTs showed increased levels of the antibody isotypes IgG 
(consistent with data shown before in (Schiller, Mayr et al. 2017)), IgA and IgM as 
compared to donor samples (Figure 24A). 
Interestingly, in immunofluorescence stainings of IPF tissue sections, FKBP11 did only 




Figure 24: Antibody yields are increased in IPF lung tissues. 
Western Blot analysis of FKBP11 and antibody isotypes IgG, IgA and IgM was performed from 
whole tissue homogenates obtained by the CPC-M bioArchive from donor samples (n=4) and IPF 
patients (n=4). An amido black staining was used as loading control (A). In addition, 
immunofluorescent stainings of IPF tissue sections obtained by the CPC-M bioArchive were 
stained for antibody isotypes IgG, IgA or IgM and FKBP11. For each antibody isotype, three IPF 
tissue sections (n=3) were stained, and one representative image was shown for each isotype (B). 
In IPF, protein levels of FKBP11 and the antibody isotypes IgG, IgA and IgM were increased as 
compared to control (ctrl) (A). In immunofluorescence, FKBP11 colocalized mainly with IgG+ 
and IgA+ cells, but not with IgM+ cells (B). ACTB = β-actin as loading control. Scale bar: 50µm. 
 
In summary, these results support a potential impact of antibodies and thereby 




A profound knowledge of the process of antibody folding as well as plasma cell 
differentiation may not only pave the way for the development of antibody-based 
therapeutic compounds, but could also provide novel targets in treatment of autoimmune 
diseases and idiopathic pulmonary fibrosis (IPF), a fatal disease with autoimmune 
features. On the contrary, the process of antibody folding in the endoplasmatic reticulum 
(ER) along with antibody folding catalysts is still uncompletely defined. In this study, the 
immunophilin FKBP11 was found to be a novel, plasma cell-specific antibody folding 
catalyst. FKBP11 was highly increased in IPF and specifically expressed by tissue 
resident plasma cells in both IPF lungs and lymphoid organs. B cell to plasma cell 
differentiation, as well as induction of ER stress, upregulated FKBP11 in an XBP1-
dependent manner, while silencing of FKBP11 in a human lung carcinoma cell line 
resulted in a high susceptibility towards ER stress induced cell death. Finally, FKBP11 
catalyzed antibody folding in vitro. In accordance, silencing of FKBP11 in an antibody 
secreting hybridoma cell line lead to a decline in secreted antibodies. 
6.2 FKBP11 is a plasma cell specific protein and increased in IPF 
IPF is an interstitial lung disease (ILD) defined by chronic, progressive scarring of the 
lungs, ultimately leading to death within few years (Fernandez and Eickelberg 2012). The 
pathogenesis of IPF is uncompletely understood, and autoimmune processes are 
becoming increasingly evident to be involved (Xue, Kass et al. 2013, Hoyne, Elliott et al. 
2017, Schiller, Mayr et al. 2017). In the current study, protein levels of FKBP11 were 
highly increased in IPF as compared to healthy donor lungs (Figure 11), which is 
supported by data from a preceding proteomics study with FKBP11 being among the 
significantly upregulated proteins (Schiller, Mayr et al. 2017). Another FKBP protein, 
FKBP10, has been upregulated in the same proteomics study, which is consistent with 
previous publications identifying FKBP10 as profibrotic mediator in IFP and a novel drug 
target in IPF treatment (Staab-Weijnitz, Fernandez et al. 2015, Knüppel, Heinzelmann et 
al. 2018). Taken together, these results support a role of FKBP proteins within IPF 
disease. 
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Immunofluorescence revealed that FKBP11 was specifically expressed by CD45-/CD20-
/CD38+/CD27+/CD138+ plasma cells in IPF (Figure 12 and Figure 13). Importantly, 
CD20+ B cells did not show expression of FKBP11 (Figure 12B), suggesting FKBP11 to 
be an exclusive feature of plasma cells, which they obtain after completing differentiation 
from naïve B cells. This was confirmed by an in vitro B cell to plasma cell differentiation 
assay (adapted from (Pinna, Corti et al. 2009)), showing that FKBP11 is upregulated 
within the process of B cell to plasma cell differentiation (Figure 16). In addition, CD38+ 
plasma cells in primary and secondary lymphoid organs, including thymus, tonsils, 
spleen, and small intestine, showed colocalization with FKBP11 (Figure 12C), speaking 
in favor of FKBP11 to be a protein which is expressed by plasma cells in general. In 
agreement, overexpression of FKBP11 using a transgenic lentiviral mouse model has 
been shown to favor plasma cell differentiation upon lipopolysaccharide (LPS) treatment. 
The same mice showed higher serum levels of basal IgG3, speaking for a higher 
proportion of plasma cells (Xue, Kass et al. 2013). Moreover, FKBP11 expression in 
peripheral B cells sorted from systemic lupus erythematosus (SLE) patients has been 
found to be associated with elevated numbers of peripheral plasma blasts (Garaud, 
Schickel et al. 2011). Overall, these results argue for a crucial function of FKBP11 in 
plasma cell biology. 
In accordance with increased protein levels of FKBP11 in IPF, the number of 
FKBP11+/CD38+ plasma cells in immunofluorescent stainings of IPF was drastically 
elevated in comparison to healthy donor lungs (Figure 13A and B). This is supported by 
a previous publication showing elevated numbers of MZB1+/CD38+ plasma cells in IPF 
(Schiller, Mayr et al. 2017). Given specific expression of FKBP11 in CD3-/CD20-
/CD38+/CD27+ plasma cells in IPF lung tissue (Figure 12), this cell population was gated 
in peripheral blood of IPF patients and healthy controls and analyzed using FACS 
analysis. In contrast to IPF lung tissue, the proportion of circulating plasma cells over all 
viable cells in IPF patients was very small (0.3%) and did not significantly differ from 
healthy controls (Figure 13C). This result suggests that the majority of plasma cells in 
IPF lungs differentiates from resident B cells, rather than migrating from peripheral 
organs. Opposed to this, a preceding study has found the proportion of plasmablasts 
(CD2+/CD38+) over all gated B cells from peripheral blood of IPF patients 
(CD19+/CD20-/CD3-/IgD-) to be increased in IPF (Xue, Kass et al. 2013). However, this 
result is barely comparable with the findings of the present study, as the present study did 
not gate for CD19, because it has been stated that a high proportion of plasma cells loses 
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expression of CD19 (Table 1, (Caraux, Klein et al. 2010)). Further, the present study did 
not standardize with regard to B cells, but to all viable cells gated. 
As outlined above, autoimmune features, including autoantibodies, are increasingly 
recognized to play a role in the pathogenesis of IPF (Kahloon, Xue et al. 2012, Xue, Kass 
et al. 2013, Donahoe, Valentine et al. 2015, Schiller, Mayr et al. 2017). As increased 
levels of IgG, IgA and IgM (Figure 24A), as well as strong expression of FKBP11 along 
with high numbers of FKBP11+ plasma cells in IPF lungs (Figure 11 and Figure 13) were 
observed, a role of autoimmunity in IPF is supported. Interestingly, treatment with 
tacrolimus (FK506), which in our study significantly inhibited FKBP11-mediated 
antibody folding in vitro (Figure 23B), has been associated with improved medial survival 
durations, and lower rates of re-acute exacerbations in patients with acute exacerbations 
of IPF (Horita, Akahane et al. 2011). In addition, tacrolimus has been shown to inhibit 
collagen synthesis in vitro, and to attenuate lung fibrosis in the bleomycin (BLM) induced 
lung fibrosis model (Nagano, Iyonaga et al. 2006). However, application of tacrolimus in 
the acute injury phase of the BLM model has been seen to result in deterioration of the 
lung injury (Nagano, Iyonaga et al. 2006). Tacrolimus only binds FKBP11 with low 
affinity in vitro (Rulten, Kinloch et al. 2006), and has been ascribed to bind FKBP1A 
with the highest affinity (Kang, Hong et al. 2008), making it questionable whether 
tacrolimus can have an impact on IPF that is particularly mediated via inhibition of 
FKBP11. As a consequence, it still remains elusive whether the observations on FKBP11 
in IPF found in the present study represent epiphenomena occurring as a part of unspecific 
inflammation processes, or actual disease-promoting autoimmune mechanisms. A 
targeted therapy aiming at plasma cells in particular, e.g. in the form of anti-CD 38 
antibodies as they are currently in clinical trials for multiple myeloma (van de Donk, 
Janmaat et al. 2016), could provide new insights on this. 
6.3 Plasma cell differentiation and the unfolded protein response upregulate 
FKBP11 
To prepare for biosynthesis and secretion of enormous amounts of antibodies, plasma 
cells need to massively expand their rough ER along with upregulation of ER-resident 
chaperones and folding catalysts. This is achieved within the process of B cell to plasma 
cell differentiation by activation of the unfolded protein response (UPR), a reaction that 
is usually triggered by ER stress caused by accumulation of misfolded proteins. More 
precisely, two master regulators of B cell to plasma cell differentiation have been 
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identified to mediate the UPR: PRDM-1 and XBP1, while XBP1 is a downstream effector 
of PRDM-1 (Iwakoshi, Lee et al. 2003, Nutt, Hodgkin et al. 2015, Grootjans, Kaser et al. 
2016, Minnich, Tagoh et al. 2016). 
Here, FKBP11 was induced upon B cell to plasma cell differentiation (Figure 15 and 
Figure 16). In consistency with a role of FBKP11 in protein folding, FKBP11 was 
upregulated upon induction of ER stress via tunicamycin in two distinct cell lines (Figure 
17), namely A549 (derived from human lung adenocarcinoma) and RAJI (derived from 
human B cells). In both cell lines, FKBP11 was ER-resident, as assessed by subcellular 
fractionation (Figure 18). Furthermore, knockdown of XBP1 with subsequent induction 
of ER stress repressed upregulation of FKBP11 (Figure 19), indicating that upregulation 
of FKBP11 is mediated by XBP1. This is in agreement with previous findings, showing 
ER stress dependent upregulation of FKBP11 (Jeong, Jang et al. 2017, Wang, Cui et al. 
2018) and pointing towards FKBP11 being a transcriptional target of XBP1 (Shaffer, 
Shapiro-Shelef et al. 2004, Wang, Deng et al. 2019).  
Of note, induction of ER stress via tunicamycin in A549 cells with prior knockdown of 
FKBP11 was associated with a decline in cell viability upon tunicamycin treatment 
(Figure 20), illustrating an increased susceptibility towards ER stress induced cell death. 
This is in agreement with a previous study, showing that overexpression of FKBP11 in 
inflamed intestinal epithelial cells, displaying features of ER stress, attenuates expression 
of pro-apoptotic markers along with a decrease in apoptosis (Wang, Cui et al. 2018). 
Whether this decline in cell viability is a consequence of an accumulation of misfolded 
proteins in the ER due to an impaired folding machinery, or the consequence of a loss of 
a pro-survival factor, remains elusive. However, given the function of FKBP11 in 
antibody folding (see 6.4), the former is more likely. Overall, these results indicate that 
plasma cells upregulate FKBP11 in an XBP1-dependent manner as a part of the UPR and 
support an important function of FKBP11 within the ER in the process of UPR in general.  
6.4 FKBP11 acts as a competent antibody folding catalyst 
Antibody function strictly relies on a functional, three-dimensional structure. This is 
assured by a sufficiently functioning folding machinery in the ER, consisting of several 
chaperones and folding catalysts including heat shock proteins (Hsp), peptidyl-prolyl cis-
trans isomerases (PPIases), glycan-binding proteins and oxidoreductases (Feige, 
Hendershot et al. 2010, Feige and Buchner 2014). Importantly, the process of peptidyl-
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prolyl cis-trans isomerization, an intrinsically slow reaction catalyzed by PPIases, 
determines the rates of many protein folding procedures and is involved in regulatory 
events in folded proteins (Göthel and Marahiel 1999). Likewise, antibody domains are 
rich in prolines, making up 5-10% of their primary sequence. The proline residues have 
been suggested to protect antibody domains from cleavage by extracellular proteases, and 
to reduce aggregation tendency (Feige and Buchner 2014). Thus, PPIases are universally 
acknowledged to play an important role within antibody folding. Still, the knowledge on 
PPIases involved in antibody folding is rather superficial, and a role of PPIases within 
human plasma cells is poorly characterized. So far, only two distinct PPIases have been 
proposed to be involved in the process of antibody folding, namely Cyclophilin B (CypB) 
(Meunier, Usherwood et al. 2002, Feige, Groscurth et al. 2009, Jansen, Määttänen et al. 
2012, Lee, Choi et al. 2012) and FKBP1A (FKBP12) (Lilie, Lang et al. 1993). In the 
present study, FKBP11 was identified as a novel antibody folding PPIase within human 
plasma cells (Figure 12 and Figure 23). 
With FKB1A, the first association of immunophilins of the FKBP family with antibody 
folding has been made. Using an in vitro refolding assay similar to the refolding assay 
used in the present study, denatured IgG fab fragment has been refolded either under 
addition of recombinant FKBP1A or a vehicle control. Addition of recombinant FKBP1A 
has accelerated the refolding process, and has resulted in an increased yield of refolded 
antibodies in total (Lilie, Lang et al. 1993). However, given that FKBP1A is a protein 
specifically expressed in the cytosol (Tong and Jiang 2015), it is unlikely to fold 
antibodies in vivo, as this process takes place in the ER (Hendershot and Sitia 2004, Feige, 
Hendershot et al. 2010, Feige and Buchner 2014). 
CypB is universally accepted as an ER-resident antibody folding PPIase (Feige, 
Hendershot et al. 2010). This concept has been established upon the following key 
findings: First, recombinant CypB has been shown to catalyze antibody folding in vitro 
within the same assay as used for FKBP1A (Lilie, Lang et al. 1993). This result was 
confirmed by our refolding assay, in which CypB served as a positive control (Figure 23). 
Second, using a crosslinking approach, CypB has been found to be a part of a large ER-
localized multiprotein complex that is associated with unassembled and uncompletely 
folded Ig heavy chains (Meunier, Usherwood et al. 2002). Moreover, (Lee, Choi et al. 
2012) have reported that inhibition of the PPIase domain of CypB by its natural binding 
partner, cyclosporin A (CsA), impairs antibody folding on a posttranslational stage in a 
Discussion 78 
murine, antibody secreting hybridoma cell line, as well as in primary B cells. More 
recently, a novel complex between CypB and the protein disulfide isomerase (PDI) 
ERp72 (PDIA4) has been identified within the ER by ER-specific pulldown and a yeast-
two hybrid system. Taking advantage of a CH1-CL assembly assay (first described in 
(Feige, Groscurth et al. 2009)), which can monitor disulfide bond formation between the 
constant parts of the IgG heavy and light chain, CypB has been observed to augment PDI 
activity of ERp72 (Jansen, Määttänen et al. 2012). 
Despite all this evidence for a function of CypB in antibody folding, the relative 
contribution of CypB remains elusive. So far, no study has addressed specific expression 
of CypB in plasma cells. On the contrary, CypB is known to be expressed ubiquitously in 
almost all tissues (Ryffel, Woerly et al. 1991), arguing for a far more general role of CypB 
in protein folding. Moreover, upregulation of CypB within the process of B cell to plasma 
cell differentiation, which would underline the importance of CypB for antibody folding 
in plasma cells, has not been observed. 
In the present study, in contrast, human FKBP11 was characterized as a novel, plasma 
cell specific PPIase with strong in vitro and in vivo evidence. Using an in vitro refolding 
assay, we demonstrated that the purified FKBP domain of human FKBP11 accelerated 
the rate of IgG refolding and increased the yield of totally refolded IgG (Figure 23A). 
Inhibition of the PPIase activity with tacrolimus, on the other hand, repressed these effects 
(Figure 23B), which confirms that the PPIase domain of FKBP11 is capable of antibody 
folding in vitro. Consistently, FKBP11 colocalized with at least two major antibody 
isotypes, namely IgG and IgA, in lung tissue from IPF patients (Figure 24B). Knockdown 
of FKBP11 in an antibody secreting hybridoma cell line, innately showing high levels of 
FKBP11 (Figure 21A), led to a decline in IgG levels in the cell culture supernatant (Figure 
22), additionally highlighting the importance of FKBP11 for antibody folding in plasma 
cells. In the same cell line, ER-residency was confirmed by confocal microscopy, 
illustrating colocalization of FKBP11 with Concanavalin A (Figure 21C), a known ER-
resident protein, and by subcellular fractionation, indicating a similar enrichment pattern 
as the ER resident protein calreticulin (Figure 21B). Furthermore, FKBP11 was 
exclusively expressed by plasma cells (Figure 12A and C), whereas naïve B cells did not 
display relevant expression (Figure 12B). This was additionally confirmed by a human 
test system illustrating that plasma cell differentiation induced by a combination of IL-2 
and R848 was accompanied by upregulation of FKBP11 (Figure 15 and Figure 16). 
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Finally, FKBP11 was identified as a transcriptional target of XPB1 (Figure 19), which is 
known to induce the UPR along with plasma cell differentiation (Iwakoshi, Lee et al. 
2003).  
With this, FKBP11 might be a potential drug target for autoimmune diseases and IPF. 
Tacrolimus inhibited the effects of FKBP11 on antibody folding (Figure 23B). Moreover, 
tacrolimus has been reported to inhibit plasma cell proliferation and differentiation, which 
might have been mediated by an effect on FKBP11 (De Bruyne, Bogaert et al. 2015). In 
an independent study, however, this finding was not supported (Traitanon, Mathew et al. 
2015). Also, the concentrations used for inhibition of FKBP11 by tacrolimus were high 
(180μM), and unlikely to be achieved at this concentration in the plasma of patients due 
to toxic side effects of tacrolimus. This is in agreement with preceding studies, reporting 
FKBP11 to bind tacrolimus only weakly in vitro (Rulten, Kinloch et al. 2006). As a 
consequence, FKBP11 is unlikely to be used pharmaceutically as a target of tacrolimus. 
Therefore, new strategies need to be developed to target FKBP11 more specifically, 
which could then provide more perspectives in the form of novel targeted therapies. 
Besides its potential as a novel drug target, FKBP11 could be a possible tool to improve 
recombinant antibody production in cultivated mammalian cells. The majority of 
therapeutic proteins, including antibodies, are produced in cultivated mammalian cells 
with titers reaching more than 10g/L (Wurm 2004, Kim, Kim et al. 2012). Still, due to an 
increasing biopharmaceutical market, productivity needs to be enhanced. Importantly, the 
limiting factor in enhancing productivity is considered to be posttranslational 
modifications, such as protein folding, assembly and secretion of the protein (Kim, Kim 
et al. 2012). A previous study has shown that overexpression of CHOP, a UPR related 
protein, increases antibody production in chinese hamster ovary (CHO) cells (Nishimiya, 
Mano et al. 2013). Moreover, overexpression of XBP1 has led to enhanced secretory 
capacity of CHO cells (Tigges and Fussenegger 2006). Similarly, overexpression of 
FKBP11 could result in increased productivity of antibody producing cells, given its 
function in antibody folding. 
6.5 Conclusions and outlook 
In conclusion, FKBP11 was identified as a novel, plasma cell specific antibody folding 
catalyst, that is highly increased in IPF. It was upregulated as a transcriptional target of 
XBP1 within B cell to plasma cell differentiation as a part of the UPR and its knockdown 
Discussion 80 
resulted in reduced antibody folding capacity as well as increased susceptibility towards 
ER stress induced cell death. Figure 25 gives an overview on the regulation and function 
of FKBP11. 
 
Figure 25: Regulation and function of FKBP11.  
Binding of an antigen to its respective B cell receptor (BCR) on the cell surface of a B cell results 
in B cell activation and plasma cell differentiation. As a result of B cell activation, the unfolded 
protein response (UPR) is induced, leading to increased levels of spliced XBP1 (sXBP1). sXBP1, 
in turn, serves as a transcription factor and thereby induces expression of FKBP11. Once 
translocated into the endoplasmatic reticulum (ER), FKBP11 contributes to antibody folding in 
the ER by its peptidyl-prolyl cis-trans isomerase activity. 
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These results aid a better understanding of B cell and plasma cell biology, as well as the 
process of antibody folding. By this, novel strategies are implied to enable a greater 
manipulation of the humoral immune system both to improve immunity and to thwart 
autoimmune pathologies. Furthermore, it can be helpful to overcome current limitations 
in the production of monoclonal antibodies. Still, further investigations are necessary to 
see if FKBP11 in particular will be useful as a drug target in this context or can even be 
utilized as a recombinantly produced compound. 
Finally, these findings highlight the importance of FKBP proteins in human diseases. 
While this study supports a role of FKBP11 in IPF and autoimmune diseases, other 
FKBPs have been proposed to be implicated in numerous pathologies, including cancer, 
cardiac diseases and neurodegenerative disorders. As a consequence, it is becoming 
increasingly evident, that a systematic and detailed analysis of tacrolimus and its 
analogues as inhibitors of not only FKBP1A, but also other FKBP proteins, will provide 
new therapeutic options for various pathologies. 
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